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Platelets are important for clot formation and vascular integrity. Thrombocytopenic patients 
with hematological disorders are at risk of bleeding and platelet transfusions are important in 
supportive care and treatment of lite-threatening bleedings. Transfusion response in terms of 
platelet increment is highly variable and hard to predict in the individual patient. Platelet 
transfusion refractoriness is often due to non-immune factors such as fever, bleeding or 
infection. Of the immune-causes, antibodies against Human Leukocyte Antigen (HLA) class 
I is the most common, and these patients can receive HLA-matched platelet transfusions. In a 
more experimental approach HLA deficient platelets are created by acid treatment.  
The overall aim of this thesis was to gain a better knowledge of factors affecting platelet 
transfusion outcome and platelet function, and to improve transfusion practice to patients 
with platelet refractoriness due to anti-HLA antibodies. In the included research papers, we 
focused on platelet function and clot formation in patients before and after platelet transfusion 
(paper I), response to HLA matched platelet transfusions (paper II) and function and 
survival of HLA deficient platelets (paper III and IV).  
In paper I, we evaluated the effect of platelet transfusions in 40 hematology patients, 
measuring platelet count increment, clot formation and response to agonist activation. Platelet 
count increment correlated with improved clot formation, but the response was highly 
variable and 34 % of the patients did not respond to the transfusion. In responder patients, 
efficient clot formation was predicted by good platelet responsiveness to agonist stimulation, 
but transfusion did not, however, restore platelet function to that of healthy controls. In paper 
II we evaluated HLA matched platelet transfusions to platelet refractory hematology patients. 
We found that selection of platelets with either a complete HLA match, or an acceptable 
HLA mismatch, was highly predictable for a successful transfusion response. For HLA-
mismatched transfusions, the degree of matching correlated with the fraction of successful 
transfusions. Many transfusions were successful despite the presence of donor-specific 
antibodies (DSAs). In paper III we evaluated the function of HLA deficient platelets after 
acid treatment and found that they were viable with a normal upregulation of activation 
markers. The HLA deficient platelets aggregated to a similar extent as untreated platelets in 
response to stimulation with agonists. Acid treatment removed 70 to 90% of all HLA Class I 
complexes, which was followed by protection from anti-HLA antibody-mediated 
complement lysis and reduced phagocytosis by monocytes in vitro. In paper IV we further 
evaluated the function of HLA deficient platelets in whole transfusion units and investigated 
the survival of HLA deficient platelets in a mouse model. Recovery, HLA reduction, and 
viability in acid-treated platelet bags were comparable to the small-scale treatment protocol, 
and platelets contributed normally to clot formation. The HLA deficient platelets also 
contributed to endothelial integrity. Acid-treated platelets showed a lower in vivo recovery 
compared to untreated platelets in the mouse model. They were protected from rejection by 
single HLA allele-specific antibodies, but still cleared by a pan-HLA antibody. 
In summary, the results and conclusions presented in this thesis provide a basis for adjusted 
transfusion practices and several hypotheses for future research. Our results also take HLA 
deficient platelets closer to a clinical trial.  
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Platelets are the cellular mediators of clot formation and therefore an important part of the 
defence against bleeding. Many patients with hematological disorders experience low platelet 
counts in peripheral blood, a condition also known as thrombocytopenia. The 
thrombocytopenia may result from the hematological disorder itself or be due to bone 
marrow suppression after intensive chemotherapy[1]. Low platelet counts increase the risk of 
bleeding and patients with thrombocytopenia may need platelet transfusions[2]. The platelet 
transfusions can be given either prophylactically to prevent bleeding or therapeutically at 
signs of bleeding. The presented thesis has two main objectives: 1) platelet function in 
patients with hematological malignancies and what effect platelet transfusions have on 
platelet function in such patients and 2) patients that do not obtain the full effect of platelet 
transfusions due to alloimmunization with Human Leukocyte Antigen (HLA) antibodies, 
including exploration of an alternative transfusion strategy with HLA deficient platelets.  
1.1 HEMATOPOIESIS 
Hematopoiesis refers to the formation of all blood cells from hematopoietic stem cells 
(HSCs), a process that in adult humans primarily takes place in the bone marrow. HSCs are 
multipotent and have the capacity to self-renew[3]. HSCs are defined by the expression of 
CD49f and other markers[4]. Their multipotency give rise to two specific paths, the myeloid 
pathway via common myeloid progenitors (CMPs) and the lymphocytic pathways via multi-
lymphoid progenitors (MLPs)(Figure 1). CMPs differentiate into red blood cells 
(erythrocytes) and platelets (thrombocytes) via myeloid erythroid progenitors (MEPs), and 
cells involved in cellular immunity such as granulocytes via granulocyte-macrophage 
progenitors (GMPs). MLPs differentiate into T cells (T stands for thymus, the organ in which 
the T cells mature), B cells (B comes from the name of the place they were discovered, the 
Bursa of Fabricius which is an organ in birds) and NK (natural killer) cells. 
                      
Figure 1. Schematic overview of HSCs developmental journey. HSCs develop into the 
terminally differentiated cell populations on the far right in this figure. Multipotent progenitors (MPPs) can be 
distinguished from HSCs by the loss of CD49f expression. Adapted from [4]. 
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1.1.1  Megakaryocytopoiesis and platelet formation 
A long time has passed since William Osler first described what is now believed to be 
platelets in his papers in 1873 and 1874[5]. Identification of the platelet’s role in clot 
formation is accredited to Giulio Bizzozero who in 1881–1882 performed elegant 
intravascular microscopy and in vitro flow chamber studies[6]. Bizzozero was likely the first 
to describe megakaryocytes in the bone marrow but it was not until the early 20th century 
that James Homer Wright suggested that they were the progenitors of platelets, at this time 
called “dust of the blood”[7]. The description is easily understood knowing that the platelet is 
in average 2-4 µm in diameter, and the smallest of the blood cells. However, the platelet is 
enucleated, basically being just little shreds of membrane-enclosed cytoplasm from the 
megakaryocytes and therefore does not count as the smallest cell of the body, despite being 
smaller than the title-holding sperm. 
Megakaryocytes are rare in the bone marrow, constituting around 0,05% of the nucleated 
cells[8]. The development of megakaryocytes in the bone marrow is a unique process, 
induced by the growth factor thrombopoietin (TPO). By injecting plasma from patients with 
thrombocythemia (abnormally high platelet counts) into mice and observing the following 
transient increase in platelet counts, TPO was proven to exist in 1958[9]. The maturation of 
megakaryocytes involve duplication of the nucleus without cell division, resulting in giant 
cells averaging 50–100 μm in diameter[10]. Upon leaving the bone marrow some 
megakaryocytes reach the blood stream, some end up trapped in the lungs. The cytoplasm 
from the megakaryocyte fragments at shear stress and pieces of cytoplasm can be released in 
the bone marrow as well as in the lungs and in the blood stream. However, it has been 
suggested that it is only in the circulating blood that the fragments, or proplatelets, form into 
mature platelets. The maturation process of proplatelets involves elongation, curving, and 
finally change shape to form the platelets[11].  
Approximately 100 billion platelets are produced every day in the human body, enough to 
maintain levels of 150 000 to 400 000 platelets per microliter of blood (150-400x109/L)[12]. 
Platelets have a short life span, surviving only around 10 days in the circulation[1]. 
1.2 THE ROLE OF PLATELETS  
The process to prevent and stop bleeding is called hemostasis. The platelets are the cellular 
mediators of clot formation (thrombosis). They patrol vessels enabling quick cover and 
closure of tissue and endothelium wounds, an important part of hemostasis. In the last decade, 
important immune and inflammatory roles of platelets have also been continuously 
acknowledged.  
Platelet function, a recurring concept in this thesis, is defined as the ability of platelets to 
respond to different stimuli in the environment.  
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1.2.1  Platelet activation and clot formation 
Clot formation is usually described in a three-step model containing adhesion, activation and 
aggregation[13]. These steps develop successively but are closely integrated and partially 
overlap. Platelet adhesion, as the first step of clot formation, usually start when extracellular 
matrix (ECM) is exposed due to a vessel or tissue injury. Platelets get in contact with, and can 
adhere to, matrix components such as collagen, laminin and Von Willebrand Factor (VWF). 
For example, platelets are very quickly tethered to exposed subendothelial VWF by        
GPIb-IX-V, a receptor complex located in the platelet membrane. Adhesion to other matrix 
components are mediated through integrin receptors in the platelet membrane, such as α2β1 
for collagen and α6β1 for laminin[14].  
Platelet agonists, for example thrombin, adenosine diphosphate (ADP) and thromboxane A2 
(TxA2), play an important role in the following steps of clot formation: activation and 
extension of the platelet plug (aggregation). Thrombin is perhaps the most effective platelet 
activator, even at a very low concentration. Platelet activation with thrombin is largely 
mediated by two protease activated receptors (PARs), in humans PAR-1 and PAR-4[15]. 
Thrombin also seems to be the agonist most efficiently coupled to phospholipase C (PLCβ) 
activation, generating second messengers and leading to the release of intracellular calcium. 
Other thrombin-induced platelet responses are shape change, secretion, TxA2 generation, 
protein phosphorylation and aggregation. Schematic overview of clot formation is shown in 
figure 2.  
 
Figure 2. Schematic of platelet activation and clot formation. Clot formation starts with 
platelets adhering to exposed extracellular matrix via integrin or GPVI receptors. Release of bioactive molecules 
from dense and α-granules in the platelets act to activate additional surrounding platelets. Formation of the clot is 





In recent years it has been acknowledged that platelets are not equally activated throughout 
thrombus formation, and the core- and shell model has emerged. One study could show two 
distinct platelet populations in the clot, a core of highly activated platelets and a looser outer 
shell with less activated platelets[17].  
1.2.1.1 Some other mediators and receptors important for platelet function 
ADP is stored in dense granules in the platelets and platelet activation leads to secretion. Red 
blood cells at sites of vascular injury also release ADP. Events following platelet activation 
by ADP includes for example intraplatelet Ca2+ elevation, synthesis of TxA2, shape change, 
granule secretion, activation of the receptor αIIbβ3, and aggregation[15].  
P-selectin (CD62P) belongs to a family of receptors (selectins) with a pivotal role in 
adhesion, but also plays a role in attachment of neutrophils and monocytes to the platelets and 
endothelial cells[14]. It is present in α-granules of resting platelets and is translocated to the 
plasma membrane after activation. The expression of CD62P on circulating platelets indicates 
in vivo activation. 
The integrin receptor αIIbβ3 (CD41/CD61), also known as GPIIb-IIIa, is expressed on resting 
platelets in its low affinity state[14]. Upon activation this receptor goes through a 
conformational change to reach the high affinity state, promoting platelet aggregation by 
facilitating binding of for example fibrinogen, fibrin and VWF.  
FcγRIIA (CD32) is a member of the immunoglobulin (Ig) super family with low affinity for 
the constant fragment (Fc) of immunoglobulin G (IgG). Cross-linking of this receptor 
initiates platelet activation by for example tyrosine phosphorylation, phospholipase C 
activation, calcium signaling and cytoskeletal rearrangement[14]. 
1.2.2  Inflammation and immune responses 
The role of platelets as immune cells has gained increased understanding the last decade. 
Several studies have demonstrated that platelets impact many inflammatory processes 
ranging from atherosclerosis to infectious diseases, making platelets the most numerous 
circulating cell type with an immune function[18]. Platelets have for example been suggested 
to induce the acute phase response, the earliest response to infection or vascular injury. 
Furthermore, platelets have been shown to attract and capture circulating leukocytes by 
secretion of pro- and anti-inflammatory molecules such as CXCL4 and CXCL7, thus guiding 
them to inflamed tissues[19].  
Platelets express Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), that 
recognize various molecular structures found on bacteria, viruses, and fungi[20, 21]. For 
example, TLR4 on platelets has been shown to induce platelet binding to adherent neutrophils 
in severe disease settings such as sepsis, thus promoting formation of so-called NETs 
(neutrophil extracellular traps)[22]. NETs are structures with proteolytic activity and the 
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ability to trap and kill microbes in tissues. NETs are suggested to be the key activators of 
coagulopathy in the infection setting, and activated platelets seem to be able to enhance 
formation of these neutrophil traps[23].  
CLRs on platelets have been shown to interact with several viruses, for example Human 
Immunodeficiency Virus 1 (HIV-1), facilitating capture by platelets[24]. Platelets are even 
able to directly kill microorganisms and evidence has been presented that activated platelets 
are able to internalize the bacteria Staphylococcus aureus and HIV-1, the latter probably 
mediated by VAMP (vesicle-associated membrane protein)-3[25, 26].  
In the current COVID-19 pandemic, patients with severe disease sometimes present with 
significant thrombocytopenia correlated to a worse prognosis[27]. The thrombocytopenia has 
been suggested to be due to bone marrow inhibition, increased platelet destruction or 
increased platelet consumption[28]. It is unclear whether ACE-2, the suggested SARS-CoV-2 
receptor, is expressed on platelets[19]. Other potential receptors for platelet interaction with 
SARS-CoV-2 are TLR7 and 9, and FcγRIIA via immune complexes formed in patients with 
cross-reacting antibodies to SARS-CoV-2[29]. Further research is needed to clarify the role 
of platelets in the pathophysiology of COVID-19.  
1.3 REGULATION OF PLATELET LIFE SPAN 
Due to the numerous functions of platelets, it is extremely important to maintain the balance 
between production and clearance. Platelets are removed from circulation by several different 
mechanisms, including signals induced by aging and apoptosis as well as immune mediated 
responses. The following three main mechanisms responsible for platelet clearance have been 
described[12]. The first mechanism is glycan-lectin mediated clearance in which the platelets 
loose sialic acid in the aging process. This leads to clearance via the hepatic Ashwell-Morell 
Receptor, which in turn regulates TPO in hepatocytes as a feed-back loop. The second 
mechanism is antibody mediated. Platelets coated with antibodies directed against the 
integrin aIIbβ3 and the glycoprotein GPIbα, as part of the von Willebrand receptor complex 
(GPIbIX), are cleared via Fc receptors on macrophages and CD8+ cytotoxic T lymphocytes. 
Apoptosis mediated clearance is the third mechanism described. Platelet survival is described 
to also depend on the balance between pro-survival and pro-apoptotic members of the Bcl-2 
family, critical regulators of the intrinsic apoptotic pathway[30]. 
1.4 HEMATOLOGICAL DISORDERS 
Hematology refers to the knowledge of blood, blood-forming organs, and blood disorders, 
both benign and malignant. Examples of benign hematological disorders are inherited 
diseases such as the group of hemoglobinopathies or acquired diseases such as immune 
thrombocytopenia (ITP). The malignant hematological diagnoses will be described in more 




1.4.1  Myeloid malignancies 
Myeloid malignancies are clonal diseases originating from HSCs or later progenitor cells[31]. 
They consist of both chronic and acute diseases. In the group of chronic diseases, we find 
chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) and the 
myeloproliferative neoplasms: essential thrombocytosis (ET), polycythemia vera (PV) and 
primary myelofibrosis (PMF). Acute myeloid leukemia (AML) is the primary acute myeloid 
disease. In around 80% of the cases of AML it is a de novo diagnosis, but in some cases a 
secondary AML occur after radiation or chemotherapy for another cancer, such as breast 
cancer, or following a chronic myeloid malignancy such as MDS. They all result from 
genetic mutations that disturb important processes in the cells, such as self-renewal, 
proliferation, and differentiation. Treatment usually include chemotherapy of different kinds 
and in different combinations[32]. For some diagnoses, tremendous breakthroughs have been 
made in the last two decades. The most successful example is the treatment with Tyrosine 
Kinase Inhibitors (TKIs) for CML which has dramatically changed the prognosis and 
outcome of CML. The life expectancy of CML patients is now approaching that of the 
general population[33]. 
1.4.2  Lymphoid malignancies 
Lymphoid malignancies include a large group of lymphomas, both indolent and more 
aggressive, as well as myeloma and lymphoid leukemia. These diseases originate from the 
malignant transformation of normal lymphoid cells at various stages of differentiation[34]. 
As a group, lymphoid malignancies are the sixth most common type of malignancies in the 
world. Lymphoid malignancies can present as leukemia with primary involvement of bone 
marrow and blood, or as lymphomas with solid tumors. A few of the lymphoid malignancies 
can present as either lymphoma or leukemia, for example Burkitt lymphoma/leukemia[35]. 
1.5 PLATELET TRANSFUSIONS 
Transfusions of whole blood were first reported to stop bleedings in hemorrhagic patients by 
William Duke in 1910. He had invented a bleeding time test and could conclude that the 
bleeding time was inversely correlated with the platelet count[36]. However, it was not until 
35 years later that major progress was made in the area of platelet transfusions, when it was 
recognized that thrombocytopenia was a major cause of death after radiation exposure from 
atomic weapons[37]. In the years that followed, new chemotherapeutic agents emerged that 
resulted in thrombocytopenia in the patients. Therefore, platelet transfusions have had an 
important role in management of side effects, improving survival and thus enabling the 
development of modern chemotherapy. The first prospective randomized comparative study 
of supportive therapy with platelets was published in 1959. Platelets were then given as 
whole blood transfusions, and the study compared fresh and stored whole blood transfusions 
to children with bleeding because of leukemia treatment. Nine patients were included, of 
which 6 had a reduction or cessation of bleeding. Five out of these 6 received fresh blood. 
They concluded that the clinical effect on bleeding was significantly better in fresh 
products[38]. In 1974 a double-blinded study was performed on thrombocytopenic leukemia 
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patients where they prophylactically received either platelets or platelet-poor plasma[2]. 
Patients that had received platelets had a significantly lower frequency of bleedings and it 
was the first study to show the benefit of prophylactic platelet transfusions.  
The numbers of platelet transfusions given have been steadily increasing and approximately  
2 million platelet units are transfused yearly in the US[39]. In 2019, as many as 49,784 
platelets units were transfused in Sweden[40]. Owing to initiatives in patient blood 
management, a short-term reduction can be expected. However, in the coming 5-10 years the 
demand will increase due to demographic shifts with the aging of the population, not only in 
developed countries but also low- and middle-income countries, facing an enormous 
challenge[41, 42].  
1.5.1 Platelet transfusions in patients with hematological disorders 
Today, the most common indication for platelet transfusions is bone marrow failure. The 
inability of the bone marrow to produce enough platelets can be due to hematological 
malignancies such as MDS, or because of intensive chemotherapy for more acute diagnoses 
such as AML. Allogeneic stem cell transplantation (ASCT) is a treatment with high doses of 
cytostatic drugs, often in combination, with the aim to destroy residual malignant cells and to 
clear the bone marrow for the new donor stem cells. Understandably, this always results in 
thrombocytopenia.  
In the US as an example, between one-third and half of the total platelet concentrates 
transfused yearly are transfused to hematology/oncology patients, and approximately as many 
to surgical patients (general, orthopedic, and cardiac surgery combined)[39]. From the UK it 
is reported that up to 67% are issued to hematological patients[43]. The majority of 
transfusions to hematology/oncology patients are given prophylactically[44]. 
1.5.2 Platelet concentrates 
Platelet concentrates for transfusion were not routinely available until the 1970s[45]. Around 
this time, techniques had developed that allowed the collection of sufficient numbers of 
platelets in a platelet concentrate, and clinical effectiveness of platelets could be 
demonstrated. Recovery and survival studies demonstrated that cold stored (2° to 6°C) 
platelets had a shorter survival time in the circulation than room temperature–stored platelets, 
and room temperature storage was therefore implemented as routine for prophylactic 
transfusions in hematological patients with thrombocytopenia[46].  
There are three methods to prepare platelets for transfusion: single-unit preparation from 
whole blood using a platelet rich plasma (PRP), single-unit preparation from whole blood 
using pooled buffy coats (BC) and collection by apheresis[47]. These different methods have 
their separate advantages and disadvantages. Platelets from whole blood requires pooling to 
reach an adult platelet dose. At the Karolinska University hospital blood bank, a total of 8 
donors are pooled to make two platelet units. Pooling is associated with increased donor 
exposure and higher risk of viral transmission compared to apheresis platelets from a single 
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donor, but it also reduces the impact of individual variability in platelet function, and thus 
secures a more predictable function of the unit. 
Apheresis platelets, on the other hand, are produced at a relatively higher cost and can also be 
limited by the number of available platelet donors. A major advantage of apheresis platelets is 
that the platelet donor can be chosen for specific properties, such as HLA- and human platelet 
antigen (HPA) type and cytomegalovirus status. This may be of importance for ASCT 
patients, where it is important to reduce the risk of alloimmunization as much as possible and 
where the risk for transmission of cytomegalovirus must be kept to a minimum[48]. The 
Platelet Dose (“PLADO”) study found significantly lower increase in platelet count with 
platelets derived from whole blood compared to apheresis platelets but could not show the 
equivalence in clinical effectiveness as there was no difference in the incidence of 
bleeding[49]. The quality or apheresis-derived and buffy coat-derived platelets are generally 
considered equal nowadays, and they are handed out equally to patients in need of a platelet 
transfusion. 
Platelet concentrates can be stored for 5-7 days but is has been shown that storage time has a 
negative effect on platelet quality, a process called platelet storage lesion[50]. The loss of 
function is accompanied by morphological changes such as decreased mean platelet volume 
and increased release of platelet ⍺-granules and cytosolic proteins. A recent study implicates 
that there might be differences in platelet storage lesions between buffy coat and apheresis 
platelets, with apheresis platelets expressing higher pH and higher lactate, especially at the 
end of the storage period[51]. Storage time also seems to influence platelet increment in the 
transfused patient, as elaborated on in the next part.  
1.5.3 Platelet transfusion efficacy 
The most important aim of a platelet transfusion is to stop or prevent bleeding. Patients with 
severe thrombocytopenia are at high risk of bleeding, and when bleeding occur it can often be 
life threatening. One of the challenges in transfusion medicine research is to measure the 
clinical efficacy of transfused platelets. Ceasing of actual bleeding, rated according to the 
World Health Organization’s (WHO) bleeding scale or indirect methods like bleeding time, 
has been used historically. The WHO bleeding scale is graded from 0-4 where grade 0 equals 
no clinical signs of bleeding and grade 2 or higher usually is associated with a clinically 
relevant bleeding. For example, grade 2 can be epistaxis or hematemesis, and a grade 4 
bleeding is associated with severe hemodynamic instability or fatal bleeding[52].   
Out of simplicity, in the clinical setting, the post-transfusion platelet increment (PI) is most 
often used as a surrogate marker of transfusion efficacy where post-transfusion platelet count 
is usually performed at 1 and/or 24 hours after the transfusion. PI is the basis for other 
efficacy measurements shown below, and is performed as follows:  
PI = Post-transfusion platelet count - Pre-transfusion platelet count.  
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The percentage platelet recovery (PPR) is calculated from the platelet increment x109/L (PI), 
the blood volume in liters (BV) and the platelet dose transfused x1011 (PD):  
R (%) = PI x BV x PD-1 x 100.  
The corrected count increment x109/L (CCI) is calculated from the PI, the body surface area 
of the patient in m2 (BSA) and PD: 
CCI = PI x BSA x PD-1. 
More direct and precise methods for studying recovery and survival of the transfused platelets 
require that they can be discriminated from the patient’s own circulating platelets. Some 
studies have used radioisotope-labeled autologous platelets to track transfused platelets in 
healthy volunteers[53]. Newer methods include transfusing apheresis platelets of different 
HLA Class I types than the patient, and the HLA Class I discrepancy between donor and 
recipient can then be used to identify the transfused platelets using for example multicolor 
flow cytometry[54].  
The response from a random platelet concentrate unit varies to a large extent and the increase 
is hard to predict. Some studies have attempted to address this question. Results from the 
Trial to Reduce Alloimmunization to Platelets (TRAP) study showed a mean CCI of 13.1-
16.5, depending on the preparation technique, one hour after transfusion. Recovery measured 
as PPR varied between 40.4 and 50.7 %[55]. They further reported that significant increases 
in platelet increments were associated with ABO-compatible platelets and platelets stored for 
48 hours or less[56]. Recently a publication used flow cytometry to identify apheresis 
platelets of non-self HLA Class I types transfused in eight patients undergoing allogeneic 
stem cell transplantation. One hour after transfusion fresh platelets (5-72 hours old) showed a 
recovery of 43% with a median CCI of 18.2. For stored platelets (73-148 hours old) recovery 
was 30% and median CCI was 11.4. At 15-28 hours after transfusion, recovery was 31% for 
fresh platelets and 17% for stored platelets, with a median CCI of 13.2 for fresh platelets and 
6.4 for stored platelets[54].  
Measuring the number of viable platelets after transfusion does not give the whole picture.   
A burning question is how to assess platelet function after transfusion and some attempts 
have been made to address this issue, even though most studies assess viability more than 
function. Some recent studies have used flow cytometry to investigate platelet function after 
transfusion. One study assessed platelet reactivity toward the agonists adenosine diphosphate 
(ADP), thrombin receptor–activating peptide (TRAP) and convulxin. They used a flow 
cytometry-based assay and found a higher mean fluorescence intensity of platelet activation 
markers after transfusion. They concluded that platelet transfusion improves platelet function 
in thrombocytopenic patients[57]. A similar approach was used in another recent study, but 
agonist-induced platelet reactivity was instead correlated to clinically significant bleeding.    
A moderate correlation was observed between platelet count and expression of the platelet 
activation marker P-selectin, using four different agonists. The platelet count was not 
 
10 
significantly correlated to clinically relevant bleeding (WHO grade 2 or higher) but activation 
capacity of the platelets was. As an example, the risk of developing a significant bleeding was 
reduced by 72% for every unit increase of mean fluorescence intensity (MFI) on the platelets 
after stimulation with ADP[58].  
1.5.4 Platelet transfusion approaches 
Prophylactic platelet transfusions have been standard of care to prevent bleeding in 
hematological patients since the late 1970’s. This strategy was based on a number of small, 
randomized controlled trials (RCTs) that were published around this time[2]. In a more recent 
study, standard- and low-dose platelet transfusions were compared in patients with 
chemotherapy induced thrombocytopenia. This study was stopped early because of higher 
grade 4 bleeding in patients receiving the low dose platelet transfusions, making further 
randomization unethical[52].  
Prophylactic versus therapeutic transfusions have been compared in several studies[59, 60]. 
As an example, one study randomized 600 patients to receive, or not to receive, prophylactic 
platelet transfusions when morning platelet counts were less than 10×109/L. There were 
significantly more bleeding episodes of WHO grade 2, 3, or 4 in the no-prophylaxis group 
among patients treated with chemotherapy or undergoing ASCT[59]. However, in patients 
undergoing autologous stem-cell transplantation the rates of bleeding events of WHO grade 
2, 3, or 4 were similar in the two study groups. This differs slightly from a previous study 
showing a higher incidence of grade 2, but not grade 3 or 4, bleedings in the no-prophylaxis 
group in patients undergoing autologous stem-cell transplantation[60]. Overall, the results of 
these studies support the continuation of use of prophylactic platelet transfusions to 
hematologic patients with chemotherapy induced thrombocytopenia and patients undergoing 
ASCT. 
In the last decade, cold storage of platelets has gained new research interest, as has cryo-
preservation of platelets. In a recent study, cold-stored platelets increased platelet aggregation 
in vitro after transfusion compared to room temperature–stored platelets[61]. There was also 
no significant difference in platelet count or postoperative blood loss between transfusion 
with cold- or room temperature-stored platelets. In a different study, cold-stored platelets 
were transfused to bleeding patients during different surgical procedures[62]. All patients had 
adequate surgical hemostasis, based on reports from the clinicians. Cold-stored platelets 
clearly come with a moderately reduced recovery and markedly reduced survival but seem to 
have a short term hemostatic effect in actively bleeding patients, with the advantage of 
increasing storage time significantly[63].  
1.5.5 Platelet transfusion complications 
Common side effects of platelet transfusions are non-hemolytic transfusion reactions with 
symptoms such as fever or even rigor and chills. These reactions are most often not reported 
and the true incidence is hard to estimate[64]. The effect of universal leukodepletion on the 
incidence of febrile non-hemolytic transfusion reactions has been studied with findings that 
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the incidence decreased from 0.45% to 0.11% after leukodepletion. The reduction was 
significant[65]. 
Despite great efforts there is still a small risk of transfusing a platelet unit with bacterial 
contamination[66]. This is due to the fact that platelets, unlike other transfusion products, are 
preferably stored at room-temperature[67]. However, the number of cases where bacterial 
contamination leads to clinically relevant infection is likely small. Newer techniques for 
pathogen inactivation also have a potential to further reduce this risk[68].  
Transfusion across the ABO barrier may be necessary if no compatible product is at hand. 
Guidelines say that this is acceptable but several studies have shown that transfusion of ABO 
incompatible platelets give a significantly lower platelet increment compared to ABO-
matched transfusions[69].  
A rare, but serious, complication is called TRALI (transfusion related acute lung injury). It is 
defined as an acute lung injury that develops during or within 6 hours after transfusion of one 
or more units of blood or blood components. The most common symptoms are dyspnea, 
hypoxia, hypotension, and fever. Research led to the understanding that plasma-containing 
components from female donors with leukocyte antibodies were responsible for the majority 
of TRALI fatalities[70]. A hypothesis has been stipulated that antibodies in the blood 
component unit bind to correspondent antigens in the recipient and causes an immunological 
reaction involving granulocytes in the recipient. Granulocytes reside to a large extent in the 
lungs and the reaction leads to injury of the lung endothelium, after which pulmonary oedema 
develops[71]. Reduction strategies, such as leukodepletion of blood products and excluding 
women as plasma donors, have lowered the incidence of TRALI from 2.57 cases per 10 000 
units transfused in the US in 2006[72] to only 11 suspected TRALI reports overall and no 
TRALI deaths reported in 2012. 
1.6 PLATELET REFRACTORINESS AND THE COMPLEXITY OF HLA 
Platelet refractoriness is described as the repeated failure to obtain expected increases in 
platelet count following platelet transfusions[73]. Guidelines and previous studies[69, 74, 75] 
have often used a CCI of more than 7.5 x 109/L as a cut-off for a successful transfusion, while 
a CCI of less than 7.5 x 109/L is usually considered a poor response. Platelet refractoriness is 
commonly defined as a one-hour increment of less than 5 x 109/L in at least two consecutive 
transfusions. Refractoriness is often related to non-immune causes such as fever, infection, or 
bleeding. Of the immune causes, alloimmunization against HLA with the formation of anti-
HLA antibodies is the most important. A small part of refractoriness is also caused by 
immunization against HPA[76].  
The genes for HLA in humans are located on the short arm of chromosome 6, in other species 
this is referred to as Major Histocompatibility complex (MHC) system[77]. MHC or HLA are 
important structures in the recognition of foreign antigens, allogeneic (non-self) cells and 
autologous (self) abnormal cells[78]. HLA class I, II and III have different structure and 
functions. Class I, present on all nucleated cells and on platelets, is divided into HLA A-, B- 
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and -C. Platelets predominantly express HLA-A and -B. The main function of HLA Class I is 
to present antigenic peptides to responding T cells, and the HLA molecule consist of two 
non-covalently linked polypeptide chains: an α chain or heavy chain (with three globular 
domains (α1, α2, and α3) and a subunit called β2microglobulin (β2m).  
The HLA system is the most polymorphic gene cluster in the human genome, and this 
diversity affect which amino acids are in the peptide-binding site of the HLA molecule and 
thus their binding specificity. The polymorphism of the HLA system is important in an 
evolutionary aspect, increasing the likelihood that virtually any microbe can be recognized by 
at least some individuals[77]. More than 9.000 HLA alleles have been recognized, of which 
more than 7.000 belong to HLA Class I. Each HLA allele name has a unique number 
consisting of up to four sets of digits separated by colons[79]. The HLA denotation system is 
explained in figure 3. In the context of platelet refractoriness, organ transplantation, and 
ASCT the polymorphism of the HLA system is problematic and compatible donors may be 
hard to identify.   
 
Figure 3. System for nomenclature of HLA alleles.  
Platelet refractoriness caused by anti-HLA antibodies is a serious condition associated with 
increased mortality and risks for delayed therapeutic interventions[80]. Anti-HLA antibodies 
involved in platelet refractoriness are primarily composed of IgG and are directed toward 
HLA-A and -B[81]. Exposure to foreign HLA antigens at pregnancy, via transfusion of 
different blood components, and/or organ transplantation are the primary reasons for anti-
HLA antibody development.  
At least three possible mechanisms for anti-HLA antibody-dependent platelet destruction 
have been proposed, graphically envisaged in figure 4. It has been shown that antibody-
coating of platelets leads to complement opsonization and formation of membrane attack 
complexes (MACs), leading to reduced platelet survival in vitro as well as in animal 
transfusion models[82, 83]. Fc-Receptor (FcR)–mediated phagocytosis is also proposed as an 
important clearance mechanism, with opsonization of HLA-mismatched platelets by anti-
HLA antibodies targeting them to the spleen for phagocytosis by macrophages. It has also 
been shown that anti-HLA antibodies induce FcγRIIa-dependent platelet activation and 
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enhanced phagocytosis[81, 84]. Lastly, NK cells are part of the immune cross talk in antiviral 
and antitumor responses and from our group suggest that antibody-coated platelets, in a 
similar way as reported for cancer cells, can activate NK cell degranulation (Meinke et al, 
unpublished). Whether or not NK cells play a role in platelet refractoriness remains to be 
addressed[85]. 
          
Figure 4. Schematic overview of proposed mechanisms for platelet destruction by anti-
HLA antibodies. Figure by Stephan Meinke published with permission.  
Most patients with this type of platelet refractoriness are women, which has been explained 
by the frequent occurrence of HLA immunization during pregnancy. It has been estimated in 
different studies that 10-50% of women with a history of previous pregnancies are 
immunized against HLA[86-88]. There is also a risk of immunization against foreign HLA 
class I, following transfusion with blood products as well as organ or tissue transplantation. 
Consequently, a majority of platelet refractory patients with anti-HLA antibodies are female 
patients with hematological diagnoses, most of them acute leukemia or MDS[76, 89]. 
From a clinical perspective HLA alloimmunization clearly leads to rapid clearance of 
platelets in some patients, while in others transfusion failure is rarer. It has been shown that 
patient anti-HLA antibodies bind to donor platelets resulting in IgG-opsonized platelets 
which are rapidly cleared from the circulation[81]. The efficacy of anti-HLA antibody-
induced platelet clearance differs, and several parameters may contribute to this. Firstly, HLA 
expression levels on platelets may vary between individuals. It has been shown that platelets 
with consistently low HLA-B8, B12 or B35 displayed a strongly reduced antibody-mediated 
internalization by macrophages[90]. The amount and affinity of antibodies also seem to be of 
importance. In the TRAP study, low levels of anti-HLA antibodies were not associated with 
platelet refractoriness, contrary to high titers of antibodies that were clearly related to 
refractoriness[89]. 
Universal leukodepletion was advocated in many countries around 20 years ago. This 
intervention has significantly lowered the risk of harm from platelet transfusion, including 
immunization against HLA. It has been shown that alloimmunization was significantly 
 
14 
reduced, from 19% to 7%, in Canada after the introduction of leukodepletion. Similar 
reduction was seen for alloimmune platelet refractoriness, from 14% to 4%[91]. The PLADO 
trial showed similar numbers with 5 % of the patients developing platelet refractoriness[86].  
As alloimmunization from blood products now rarely occurs, previous pregnancies are 
currently the leading cause of platelet refractoriness. The broad HLA alloimmunization, 
beyond paternal HLA specificities, seen after pregnancy has not yet been fully understood. 
One possible explanation could be that pregnancy results in antibodies specific for epitopes 
that are common across several HLA specificities[92].   
1.6.1 HLA selected platelets 
Strategies to select platelets for refractory patients include platelets from HLA-matched 
donors, avoidance of known anti-HLA antibody specificities, and platelet cross-matching 
which gives a better outcome compared to transfusion with standard platelets[75, 93].  
For selection of platelets from HLA-matched donors, the recipient and the platelet donor are 
matched for HLA-A and B, as these are most involved anti-HLA antibodies causing platelet 
refractoriness[94]. For this type of matching, the HLA class I type of patient and donors need 
to be known. The degree of match can be determined based upon a classification system 
described in detail in Table 1. Briefly, a grade A match is defined as all donor HLA antigens, 
two A- and two B-alleles, being identical to the recipient. In paper II, this was referred to as a 
complete HLA match.  
HLA matching can also be done according to the CREG (cross-reactive epitope group) 
classification system[95]. It has been shown that many epitopes, the part of an antigen that is 
recognized by antibodies, are shared among several HLA molecules[96]. Anti-HLA 
antibodies can be directed against these shared epitopes, resulting in cross-reactivity with 
numerous HLA alleles. As an example, the 9 HLA-A alleles in the A1 CREG share one 
common epitope. As a consequence, the immune system of a patient with HLA-A11 will not 
recognize HLA-A80 as foreign, since HLA-A11 and -A80 belong to the same CREG.  
HLAMatchmaker was introduced as a computer-based matching algorithm. It originally 
considered linear sequences of three amino acids (triplets) in antibody-accessible positions on 
HLA molecules. The triplets could be considered key elements of epitopes that can induce 
the formation of antibodies[97]. This was later developed into the eplet version, taking into 
consideration the three-dimensional structure of HLA molecules. Triplets and eplets may be 
identical, but eplets may also consist of amino acids positioned with some distance that 






Adapted from [95]. 
The practice to use platelets from HLA-matched donors is advocated throughout the 
world[93, 99], but suffers from several problems, of which shortage of optimally matched 
donors is the most important. Lack of donors poses a particular problem because it 
necessitates transfusion of partially mismatched platelets, with the risk for enhanced 
clearance of the platelets by pre-existing anti-HLA antibodies. This problem is particularly 
present in smaller centers in which the number of HLA-typed donors is limited, but also 
larger centers with pooled resources have problems offering all patients an optimally matched 
platelet product[76]. 
In patients tested for anti-HLA antibodies, with known specificities, choosing antigen-
negative platelets, platelets that lack the antigens to which the patient has formed antibodies, 
is an option[100]. In paper II we referred to this as having no donor specific antibodies 
(DSAs). This way of choosing platelets for refractory patients can greatly expand the number 
of compatible donors. This was exquisitely shown in a publication where 29 alloimmunized 
patients were matched for grade A, grade BU and antigen negative. With this strategy a mean 
Table 1.  HLA-Matched Platelet Classification 
 
Grade Description 
A  All 4 donor HLA antigens are identical to the recipient  
B1U  Only 3 antigens are detected in the donor (homozygous at 1 HLA allele); 
all 3 detected antigens are identical to the recipient  
B1X  2 HLA antigens are identical to the recipient and 1 HLA antigen is cross-
reactive  
B2U  Only 2 antigens are detected in the donor (homozygous at 2 HLA alleles); 
both detected antigens are identical to the recipient  
B2UX  Only 3 HLA antigens are detected in the donor (homozygous at 1 allele); 
2 antigens are identical with the recipient and 1 antigen is cross-reactive  
B2X  2 antigens are identical to the recipient and 2 antigens are cross-reactive  
C  1 antigen of donor is not present in the recipient and are not cross-
reactive with the recipient  
D  2 antigens of the donor are not present in the recipient and are not cross-
reactive with the recipient  




of 6 grade A-matched donors were found, as compared to a mean of 1426 antigen-negative, 
from a total pool of 7247 HLA-typed donors[101]. 
Another alternative is cross-matching in which neither the HLA type of the patient or the 
donor is necessary. Methods used include solid-phase red cell adherence (SPRCA), modified 
antigen capture ELISA (MACE) and flow cytometry[100]. These methods only detect 
antibodies in the sera of patients directed against the antigens of the tested platelet product, 
but not all antibodies in the patient. The biggest advantage of cross-matching is that it is done 
on platelets already available in store at the blood bank, and it does not require a large register 
of HLA typed donors. However, it is not optimal in patients that are broadly HLA-immunized 
due to the low probability of finding a compatible platelet unit with this method.  
1.6.2 HLA deficient platelets  
The use of platelets ‘stripped’ of HLA antigens, by chloroquine treatment, for platelet 
transfusions to alloimmunized patients was suggested in 1984[102]. However, the study had 
not assessed platelet function after chloroquine treatment and the authors doubted whether the 
treated platelets would be effective in hemostasis. 
Acid treatment as a method to eliminate HLA class I molecules from the surface of viable 
cells was reported in 1987 by a Japanese research group[103]. They found that a brief 
incubation at low pH (pH 3) significantly reduced expression of HLA-A, B, C and β2-
microglobulins on the cell surface of human mononuclear cells and MHC class I of mouse 
lymphocytes. A few years later a study on acid-treated platelets was published[104]. They 
could show a platelet viability of 83% after acid treatment. Platelet function studies were 
performed and showed that acid-treated platelets aggregated almost to the extent of PBS-
treated platelets. Furthermore, sera from immunized patients with multispecific anti-HLA 
antibodies reacted with PBS-treated platelets, but not with acid-treated platelets. The platelets 
showed no morphological changes with the methods used, and platelet-specific glycoproteins 
were not affected.  
It has been suggested that the acid treatment results in removal of complete HLA 
molecules[105]. However, our data in paper IV and other studies support the proposed 
mechanism that low pH leads to dissociation of β2m with the free heavy chain firmly 
remaining in the platelet membrane[106].  
Results from the first transfusion with acid treated platelets in one patient and two healthy 
volunteers was published in 1991[107]. In the two healthy volunteers, platelet recovery was 
similar for acid-treated platelets and untreated control platelets, but platelet survival time 
decreased after acid treatment. In the alloimmunized patient the first transfusion of acid-
treated platelets yielded a CCI of 11.3 x 109/L while the second transfusion only gave a 
moderate CCI. The following few studies on acid treated platelets for transfusions showed 
mixed results[108-110]. With the introduction of leukoreduced blood products from the late 
1990s and the following reduction in the frequency of alloimmunization, the interest in HLA-
depleted platelets faded.  
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1.7 EX VIVO PRODUCTION OF HUMAN PLATELETS 
Ex vivo production of platelets has been viewed as a method of resolving both shortage of 
transfusion products and certain safety issues, such as refractoriness. Induced pluripotent 
stem cells (iPSCs) are cells with pluripotent and self-renewing capacities that has been used 
to manufacture many different cell types ex vivo, including platelets. In relation to 
refractoriness, such platelets could be obtained from HLA typed iPSCs to match the 
refractory patient or be made HLA-depleted by manipulation of HLAs and HPAs. As 
mentioned before, demand is also expected to increase within 10 years, and ex vivo platelets 
would be a valuable addition to the standard collection procedures. However, so far, the 
challenge has been to make ex vivo platelets at large scale production. It was recently 
reported that over 100 billion platelets were produced, with in vitro and in vivo evaluation 
showing functionality comparable to donor-derived platelets[111]. The amount is still not 




2 STATE OF THE ART PRIOR TO THIS THESIS 
Even though several methods have gained ground in assessing platelet function and bleeding 
risk in hematological patients in recent years, platelet count remains the trigger for platelet 
transfusion. There is a strong agreement that platelet count is poorly correlated with bleeding 
risk[112, 113]. Better instruments to predict both bleeding risk and the demand for platelet 
transfusions in the individual patient would be highly valuable.  
Platelet refractory patients are relatively few, but they require extensive resources during their 
thrombocytopenic episodes. Several methods for platelet transfusion matching are used with 
their different advantages and disadvantages. To evaluate clinical outcome of HLA matched 
platelet transfusions is of utmost importance, especially considering the costs regarding both 
money, time, inconvenience for donors and psychological aspects for the patients.   
HLA deficient platelets were transfused to a handful of patients in the 1990s and showed 
varying results, as mentioned in the introduction. At that time, the preclinical testing was 
limited and there was a great lack of knowledge regarding immune system responses to these 
platelets. We therefore pursued this method in a series of experiments in a modern setting, 
with the aim to have a better understanding and characterizing of the acid treatment and the 
effect on the final HLA deficient platelets as well as immune system responses. A clinical 
study with transfusion of HLA deficient platelets is also planned. 
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3 RESEARCH AIMS 
The overall aim of this thesis was to gain a better knowledge of factors affecting transfusion 
outcome. Due to the time limitations of a thesis work more specific aims were necessary. 
 
The specific aims of the studies were: 
I. To evaluate indications and outcome of prophylactic platelet transfusions in 
hematologic patients, including platelet count increments and effect on hemostasis. 
Furthermore, we aimed to evaluate platelet function in the platelet concentrate as well 
as in the recipient, both before and after platelet transfusion.   
 
II. To characterize the responses to HLA- or cross-matched platelet transfusions, with 
regard to platelet count and clinical effects as well as antibody patterns, in a 
retrospective study of a cohort of platelet refractory hematologic patients with 
detected anti-HLA antibodies at Karolinska University Hospital.  
 
III. To evaluate function of, and biological changes in, acid-treated platelets (HLA 
deficient platelets) in order to further work toward a new transfusion principle to 
platelet refractory hematologic patients. 
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4 MATERIALS AND METHODS 
4.1 ETHICS 
4.1.1 Paper I 
The Regional Review Board of Ethics in Stockholm approved this prospective study (DNR 
2015/1413-311). Informed consent for blood sampling and data collection was obtained from 
each patient before sampling. The amount of blood sampled from each patient was calculated 
to be sufficient for the analyses, yet not more than the minimal amount required.  
4.1.2 Paper II 
The Regional Review Board of Ethics in Stockholm approved this retrospective study (DNR 
2015/1413-311). Many of the patients included were diseased at the start of the study and 
therefore informed consent was not obtained. Data published were generally on group level 
and unique patients could not be identified. Where individual data were presented, the 
patients had been given a reference number. Only the responsible researchers have access to 
the identification list.  
4.1.3 Paper III 
In this study we only used platelets remaining from production of platelet concentrates. These 
platelets are otherwise discarded. Since they consist of a pool of platelets from eight blood 
donors’ individual platelets cannot be traced or identified. The Regional Review Board of 
Ethics in Stockholm approved the study (DNR 2011/1824-311).  
4.1.4 Paper IV 
In this study we the same type of platelets as in Paper III. The study also included transfusion 
of HLA deficient platelets to immunocompromised mice. This part of the study was approved 
by Jordbruksverket (DNR S32-15 plus amendment 42-15).  
4.2 STUDY DESIGN 
4.2.1 Paper I 
Paper I was a prospective observational study of prophylactic platelet transfusions to 40 
hematological patients. The patients were admitted to the hematology ward in Karolinska 
University Hospital and were planned to receive a prophylactic platelet transfusion on the day 
of inclusion in the study. Blood sampling was done at three time-points: before, 1 hour after 
and 18-24 hours after transfusion. Outcome of transfusion, hemostasis and platelet function 
were evaluated at all time-points. Methods used were blood cell counting, flow cytometry 
and ROTEM (rotational thromboelastometry).  
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4.2.2 Paper II 
Paper II was a retrospective study evaluating 32 platelet refractory hematology patients who 
received 142 matched platelet units between 2007 and 2016. Four matching strategies were 
compared:  
1) Genomic HLA typing with low resolution (giving the allele group, but not specific HLA 
proteins, see figure 3), performed using polymerase chain reaction–sequence-specific 
oligonucleotide probing  
2) Serologic “eplet score” calculated using HLAMatchmaker.  
3) Cross-matching using lymphocyte cytotoxicity.  
4) Matching based on donor-specific antibody (DSA) specificity, determined using Luminex.  
4.2.3 Paper III 
This was a laboratory study evaluating the effect of acid treatment on platelets compared to 
control-treated or untreated platelets. Kinetics of acid stripping, viability, phenotypic 
alterations, and sensitivity to complement-mediated lysis and phagocytosis were determined 
by flow cytometry. Platelet function was evaluated using a multiplate analyzer. 
4.2.4 Paper IV 
This was a laboratory study of acid treatment in whole platelet transfusion units according to 
our scaled-up protocol. HLA removal, viability and function were assessed and compared to 
platelets treated in small scale. HLA re-association during storage of acid-treated platelets 
was evaluated. We tested the platelets ability to support endothelial integrity by measuring 
trans endothelial electrical resistance (TEER) across a cell monolayer. Finally, we tested the 
survival of acid-treated platelets in vivo using a mouse model for platelet refractoriness.  
4.3 LABORATORY METHODS 
4.3.1 Blood counts 
In paper I blood counts was measured on a Sysmex automated analyzer. In paper II blood 
counts were retrieved from the patients’ electronic medical records in Take Care (the e-health 
system at Karolinska University Hospital).  
4.3.2 Flow cytometry 
Flow cytometry was in different ways used in all papers included in this thesis. The 
technology of flow cytometry provides fast analysis of single cells in solution[114]. Flow 
cytometers use lasers as light sources to produce both scattered and fluorescent light signals 
when a cell passes the lasers. The light signals are read by detectors such as photodiodes or 
photomultiplier tubes and are then converted into electronic signals that are analyzed by a 
computer. Fluorochrome-labeled antibodies are often used to mark the receptor or molecule 
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of interest. In the flow cytometer, cell populations can be analyzed and/or purified based on 
their fluorescent or light scattering characteristics. 
Whole blood was used in the flow cytometry analyses in paper I, to not lose platelets or 
contribute to activation during preparation. This led to a large number of red cells in the 
samples and too many events per unit of time with normal scatter threshold. Therefore, 
expression of CD42a was set as the trigger in the flow cytometer settings, i.e. only cells 
above a set level of CD42a expression is saved by the computer. This allows for analyzing 
the samples in a reasonable time, given that platelets are a small part of the total number of 
cells in the samples. Using this setting roughly reduced analyzing time from 30-60 minutes 
per sample to 5-10 minutes per sample.   
4.3.1.1 Resting and activated platelets 
Resting platelets express low levels of P-selectin on the surface and GPIIb-IIIa is in its low 
affinity state. PAC-1 is a specific monoclonal antibody that binds to GPIIb-IIIa in its high 
affinity state, occurring after platelet activation. PAC-1-negative platelets are hence 
considered as resting platelets. PAC-1 positive platelets are then logically an indication of 
platelet activation[115]. P-selectin is present in α-granules of resting platelets and is 
translocated to the plasma membrane after activation, resulting in the surface expression of 
approximately 13,000 P-selectin molecules[1]. These can be identified by a monoclonal 
CD62P antibody.  
4.3.3 Rotational thromboelastometry (ROTEM) 
Rotational thromboelastometry (ROTEM ®, TEM International GmbH, Munich, Germany) 
is a viscoelastic hemostasis analysis. During clot formation fibrin networks help to increase 
the viscosity of the blood. ROTEM uses a mechanical rotating sensor that detects the 
viscoelastic changes in the clot. As the clot grows, rotation slows down. The ROTEM 
instrument graphically visualizes the stages of clot formation by a thromboelastometric curve 
(temogram), displayed on the screen together with calculated ROTEM parameters. 
Citrated whole blood is used for the assays. The blood is recalcified and clot formation is 
activated by different additives. The five principal assays used with the ROTEM instrument 
are INTEM, HEPTEM, EXTEM, FIBTEM and APTEM[116]. In our studies in paper I and 
IV, results from the EXTEM assay were reported. EXTEM uses tissue factor as an activator 
of the extrinsic pathway and reflects the clot strength dependent on platelet and fibrin 
interactions. The INTEM assay was performed in paper I, but not reported due to inconsistent 
results. INTEM uses ellagic acid and phospholipids as activators of clot formation via the 
intrinsic pathway, simulating contact activation. As in EXTEM, clot firmness reflects both 
platelet and fibrin contribution to the clot.  
Coagulation time (CT), in seconds, is the time from start of the test until a clot of 2 mm has 
formed. CT reflects thrombin generation which mainly depends on the enzymatic activity of 
coagulation factors, concentration of anticoagulant substances and fibrin split products. CT is 
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usually achieved within 1 min in the EXTEM assay. Clot formation time (CFT), in seconds, 
indicates the time it takes the clot to extend from 2 to 20 mm. CFT mainly depends on 
thrombin generation, platelet count and platelet function, as well as fibrinogen concentration 
and fibrin polymerization. One of the most important ROTEM® parameters is maximum clot 
firmness (MCF) measured in millimeters. MCF is defined as the maximum amplitude of clot 
firmness reached during the test, in other words the maximum size of the clot. MCF reflects 
the mechanical strength of the clot and mainly depends on platelet count and platelet 
function, fibrin concentration and fibrin polymerization, factor XIII activity, and colloids. 
When faster decision-making is wanted such as in patients with severe bleeding, the 
amplitude of clot firmness at 5 or 10 min after CT (A5 or A10, respectively) can be used. A5 
and A10 correlate very well with the MCF and allow for decision-making within 10–15 min 
after starting the test. EXTEM and INTEM A5 and A10 correlate with fibrinogen 
concentration and platelet count[117]. CT, CFT, A10 and MCF is shown on a temogram in 
figure 5.  
 
Figure 5. Temogram from a thrombocytopenic patient.  
Thromboelastography is useful for evaluating the overall interaction between platelet 
GPIIb/IIIa receptors and fibrinogen, as activated platelets provide ample binding sites 
(GPIIb/IIIa) for fibrinogen[116]. 
4.3.4 Multiplate 
Multiplate (multiple electrode impedance platelet aggregometer, Roche Diagnostics) is an 
instrument for analyzing platelet aggregation in whole blood. The system consists of a five-
channel computerized device, hence “multiple electrode”. It uses disposable test cells that 
contains two electrodes. Platelet aggregation on the electrodes, induced by addition of 
agonist, causes an in increase in impedance (i.e., electrical resistance) that is shown as a curve 
on the computer screen. The maximal platelet aggregation and aggregation velocity are 
converted into arbitrary aggregation units[118]. Multiplate analyses are included in paper III. 
We also used Multiplate to investigate aggregation in the patient samples before and after 
transfusion in paper I. However, Multiplate is not recommended in patients with platelet 
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counts below the reference values[119]. We could see small changes after transfusion, but as 
predicted there were no significant differences, and the results are not included in the 
manuscript.  
 
Figure 6. Multiplate graphics from analysis of a healthy donor. The most important parameter 
for aggregation is the area under the aggregation curve (AUC). 
 
4.4 ACID TREATMENT OF PLATELETS 
HLA deficient platelets are obtained by a brief incubation at low pH using treatment with 
citric acid. This removes the antigenic structure of donor HLA Class I from platelets by 
denaturation of the trimolecular HLA complexes, resulting in dissociation of β2m while the 
free heavy chain remains in the platelet membrane and can be detected by antibodies specific 
for HLA class I free heavy chain.  
In more detail, platelets from concentrates were pelleted, cooled on ice, and resuspended in 
ice-cold citric acid buffer (equal volumes of 263 mmol/L citric acid and 123 mmol/L 
Na2HPO4, resulting in pH 2.9 to 3.0) or ice-cold storage solution for platelets (SSP+, 
MacoPharma; control). Treatment was stopped by adding a 20-fold excess volume of ice-cold 
SSP+. Platelets were pelleted and resuspended in their original supernatant and counted using 
a cell counter (CASY TT, Roche Diagnostics, Rotkreuz, Switzerland; 60-mmcapillary). 
Untreated samples were adjusted to match the concentrations of the treated samples. 
4.5 MOUSE MODEL 
To assess survival of the acid-treated platelets in vivo in paper IV, a mouse model of platelet 
transfusion was set up. We chose NSG-SGM3 mice as recipient mice, as these mice carry a 
combined genetic background from NOD (non-obese diabetic) mice, SCID (severe combined 
immunodeficiency) mice and mice deficient in the common γ chain of several cytokine 
receptors. They have all the phagocytes that are thought to take part in the clearance of 
platelets from the circulation but lack lymphocytes that might react to human antigens[120]. 
To provide a permissive environment for transplantation of HSCs, they are also transgenic for 
human SCF, GM-CSF and IL-3[120]. Acid-treated, control-treated, and untreated human 
platelets were labelled with different fluorescent dyes and mixed in equal parts before 
injection into the tail vein of the mice, mimicking a platelet transfusion. One hour after 
 
28 
injection, blood was sampled from the mice and analyzed by flow-cytometry. The human 
platelets were identified by expression of human CD61 and the distribution of the three 
differently labelled populations was compared to the composition of the injected mixture. The 
flow cytometer CytoFLEX (Beckman Coulter) allows for determination of the number of 
platelets per sample volume. Thus, we could calculate how many of the injected platelets that 
still circulated in the assumed total blood volume of 1.5 ml.  
We also assessed survival of the acid-treated platelets in vivo in the presence of anti-HLA 
antibodies. At one hour after platelet injection the concentration of acid-treated, control-
treated, and untreated human platelets were assessed. Next, mouse anti-human anti-HLA 
antibodies were installed by intraperitoneal injection. Survival of injected platelet 
concentrations were again measured in blood samples acquired at two and four hours.  
4.6 ADDITIONAL METHODS 
Additional methods used in the different studies, but not described in this chapter, are 
described in detail in the methods part of each paper.  
4.7 STATISTICS 
Statistical analysis was performed with computer software (Prism 6.0 or 7.0, GraphPad 
Software, Inc., San Diego, CA or SPSS, IBM Corp.).  
In paper I and II we used nonparametric statistical methods owing to nonnormality of the 
data, i.e. Mann–Whitney U test for comparing two groups, Kruskal–Wallis for three or more 
groups and Spearman rank correlation for correlations.  
In paper III the statistical significance of differences between the results for untreated, 
control-treated, and acid-treated PLTs was determined using one way analysis of variance 
(ANOVA) with α = 5% followed by Tukey’s multiple comparisons test. 
In paper IV we used Wilcoxon matched-pairs signed rank test for the ROTEM analyses, One-
way ANOVA with Tukey’s multiple comparison test for TEER and 2-way ANOVA with 
Holm-Sidak’s multiple comparisons test for the in vivo analyses in the mouse model. 
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5 SELECTED RESULTS AND DISCUSSION 
5.1 PLATELET FUNCTION IN THROMBOCYTOPENIC PATIENTS (PAPER I) 
In this prospective study, we evaluated the effect of platelet transfusions in 40 hematology 
patients in routine clinical care, measuring platelet count increment, clot formation and 
response to agonist activation. AML was the most common diagnosis. Platelet count 
increment correlated with improved clot formation. However, the response was surprisingly 
variable between patients, and 34 % of the patients did not respond to the transfusion. Short 
time since the last platelet transfusion and extended storage time of the platelet product were 
linked to poor transfusion outcome, while patient sex, CRP levels and the number of previous 
drug cycles did not affect transfusion efficacy. In responder patients, efficient clot formation 
was predicted by good platelet responsiveness to agonist stimulation, but transfusion did not, 
however, restore poor platelet function in the AML patients to any way near healthy controls. 
Already in the 1960s it was shown that bleeding risk was increased in thrombocytopenia but 
that bleeding risk was low in platelet counts of more than 20x109/L[121]. Two more recent 
studies have shown that bleeding risk is increased at platelet counts below 80 × 109/L but 
platelet counts have no clear correlation to bleeding at counts above 10x109/l[112, 113], 
indicating that function of the platelets may play a role. The need for an approach to assess 
platelet function is evident, and what inspired us to do this study from the beginning. Our 
results show that platelet count is correlated to clot formation and platelet activation, but 
results were varying and can probably in some cases be depending on variations in the 
method itself. We could not correlate any of our findings to clinical bleeding in this study due 
to few bleeding events, however, based on other recently published studies flow cytometry 
analyses and different viscoelastic methods can to some extent predict bleeding risk[58, 122, 
123].  
Rotem is not routinely used in thrombocytopenic patients. There is no consensus on cut-off 
levels or which parameters to assess in the relevance of predicting bleeding. However, some 
studies have attempted to address this question. In ITP patients with a platelet count of less 
than 10x109/L the mean EXTEM MCF was the only parameter significantly higher in non-
bleeding patients compared to patients with bleeding symptoms, 46 mm vs 32 mm[124]. 
MCF was also positively correlated to platelet count. Statistically they found a platelet count 
of 31x109/L to be critical for affecting MCF. We did not perform similar statistics in our 
study but observed that a platelet count of more than 20x109/L often resulted in an MCF 
within the reference values (49-71mm). It seems likely that the underlying disorder is of 
importance as well as the platelet count per se, and that correlation between platelet count and 
MCF will probably be both highly individual as well as depending on the diagnosis. Focus 
should probably be directed at to what extent and at what values MCF can be used as a 
predictor of bleeding risk.  
Rotem analyses and flow cytometry have been evaluated in thrombocytopenic patients as 
methods to assess platelet function, but rarely together in a study of the effect of platelet 
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transfusions. With our study, one step is taken in the direction of a better understanding of the 
correlation between flow cytometry platelet function assays and clot characteristics. 
Thrombin has been shown to be important in the first steps of clot formation and formation of 
the compact core of the clot. ADP on the other hand seems important for attracting platelets 
to form the more porous outer shell[17]. From the results in our and other studies of 
hematological patients with thrombocytopenia it seems possible that the impaired response to 
TRAP (thrombin-simulating activation) which is more contact-dependent, would result in 
impaired formation of the core of the clot, but less so the formation of the outer shell. This 
could perhaps explain that these patients rarely bleed despite their low platelet counts, 
adhesion is not depending on thrombin and a loose clot might still be sufficient in small 
vessel and tissue injuries but not for larger injuries or surgical procedures. In extension, this 
could also provide an explanation for embolic disease in some hematological diagnoses even 
at very low platelet counts. Also, inactive platelets interact with immobilized fibrinogen and 
the very first part of clot formation is hence independent of platelet activation[125].  
It is worth noticing that it is not clarified how well whole blood aggregometry assays such as 
Rotem, or flow cytometry assays, reflect hemostasis in vivo. These methods clearly provide 
more detailed information compared to classical tests, for example the activated partial 
thromboplastin time (APTT). However, several components of in vivo clot formation 
processes, such as structure of the endothelium or dynamics of blood flow, are not included. 
A test or model including all the components of in vivo hemostasis is probably more likely to 
be found in science fiction than in clinical practice. Keeping the limitations of the different 
methods in mind when translating results into bleeding risk in the individual patient is of 
great importance.   
One parameter that has been correlated to bleeding, but that was not included in our study, is 
immature platelet fraction (IPF). It has been suggested that these young platelets, measurable 
through special staining of their high concentration of RNA, have better hemostatic 
propertied than older platelets[122, 126, 127]. Up until now IPF has not been a routinely 
available measurement, but at least in Karolinska University hospital IPF can now be ordered 
with a normal blood count. Besides IPF, size has also been implicated to matter, with larger 
platelets having more hemostatic activity[128]. None of these measurements were included in 
our study, but patients with bone marrow failure have previously been shown to have a low 
IPF in contrast to patients with immune thrombocytopenia (ITP)[127]. TPO agonists could 
theoretically lower bleeding risk in the cases where it increases IPF. A recent study showed 
that bleeding events were fewer with eltrompopag, a commercially available TPO agonist, 
compared to placebo in MDS and AML patients not receiving disease specific 
treatment[129].  
Different bleeding risks at similar PLT counts in different diagnosis have been shown[130] 
and one can speculate that the difference to some degree is dependent on platelet activation 
ability and other factors that are progressively being acknowledged to be correlated to 
bleeding. Platelet function does not seem to be generally impaired in ITP but has been shown 
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to be impaired in those with a severe bleeding phenotype[131, 132]. In our study platelet 
function was clearly impaired in the patients compared to healthy controls, supporting 
previous studies showing affected platelet function in AML patients[133-135]. The impaired 
platelet function compared to healthy individuals was also demonstrated at similar platelet 
counts by our flow cytometry assays of activation of platelets in constructed 
thrombocytopenic blood. The mechanism for platelet impairment in for example AML still 
needs to be further addressed. It has previously been shown that the megakaryocytes in the 
bone marrow of AML and MDS patients show hypogranulation and dysplastic features [136-
138]. Qualitative platelet abnormalities, such as macrothrombocytosis and platelet density 
distribution, were also demonstrated in AML more than 40 years ago[139]. Different 
chemotherapeutic agents have also been shown to affect both megakaryocytes and platelets. 
For example, different anthracyclins, common cytostatic components of AML treatment, 
enhanced platelet expression of GPIIb/IIIa and CD62P, indicating enhanced platelet 
activation by these drugs.  
Clearly no single factor can be pinpointed as predictive for platelet function and bleeding 
risk, we need a way to weigh all the factors together to reach a personalized transfusion 
strategy. For many of the assays it is also not known how well they reflect platelet function in 
vivo and we need to reach further understanding of the correlation between in vitro testing 
and in vivo function.  
5.2 HLA MATCHED PLATELET TRANSFUSIONS (PAPER II) 
Paper II is a retrospective study that evaluated HLA matched platelet transfusions to platelet 
refractory hematology patients. We found that selection of platelets with either a complete 
HLA match or an acceptable HLA mismatch based on genomic typing and DSA information, 
each was highly predictable for a successful transfusion response. For HLA-mismatched 
transfusions, the eplet score correlated with CCI and the fraction of successful transfusions. 
However, DSA matching gave an even higher correlation to a good transfusion outcome than 
Eplet score. Cytotoxic crossmatching was least predictive. For transfusions with one or more 
DSAs, the antibody reaction strength correlated with the 1-hour CCI, but many transfusions 
were successful despite the presence of DSAS. 
Several aspects need to be considered when choosing a matching strategy in a hospital or 
blood bank service, such as the cost of the matching procedure itself, HLA typing of patients 
and donors, availability etc. HLA matching by different classification systems or using 
HLAMatchmaker all require that the HLA type of both patient and donor is known, and for 
the antigen negative approach, single anti-HLA antibodies in the patient needs to be 
specified. HLA typing is done on patients eligible for ASCT but is not routine in other 
hematology patients, neither is antibody screening. Furthermore, a large donor register is 
necessary for these approaches and it also postulates that the donors are willing to come to 
the blood bank for apheresis, sometimes at short notice. Some studies have calculated the 
number of donors needed to find a well-matched donor to a certain percentage of patients. 
For example, one study reported that 18.000 donors might be needed in European populations 
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to find five completely matched donors for 80 % of all patients[140]. This is considerably 
larger than the current donor register at Karolinska University Hospital and an expansion 
towards those numbers would come at a high cost.  
One of the matching strategies evaluated in our study was epitope matching, where a 
serologic “eplet score” is calculated using HLAMatchmaker. The patients in our study were 
only HLA typed at low resolution, while the program require input of matching at high 
resolution. We therefore used the four-digit allele converter program and the ethnicity of the 
patient to calculate the most likely allele at the four-digit level, not only a drawback of our 
study but of the matching strategy itself in hospitals where low-resolution testing is standard 
procedure in platelet refractory patients. Eplet matching was recently evaluated in a RCT 
cross-over study compared with regular HLA matching. This study found it favorable to use 
eplet matching[141]. Eplet score was in our study, as mentioned, correlated to CCI and the 
fraction of successful transfusions but DSA showed even better correlation to outcome. Using 
DSA as matching strategy will also result in more potential donors, an important aspect not 
least in patients with a rare HLA type.  
Using DSA as a matching strategy on the other hand, would result in transfusion of platelets 
that are likely fully or partly mismatched but that the patient has not developed antibodies 
against yet. In this scenario the risk of further alloimmunization would have to be considered. 
To my knowledge, no clinical studies addressing this specific question has been published, 
perhaps not a surprise since it could be ethically questionable to put patients at risk for 
broader alloimmunization than necessary. Alloimmunization is also troublesome for patients 
eligible for ASCT or future organ transplantation, decreasing the likelihood of finding a well-
matched donor.  
Another method for matching that has been reported in two studies is choosing platelets with 
low expression of HLA class I[90, 142]. The first study published in 1989 could show a 
successful transfusion in 69% of events despite a HLA mismatch[142]. The second study 
only assessed antibody-mediated phagocytosis and showed that platelets with low expression 
of HLA-B8, -B12, and -B35 showed minimal antibody-mediated internalization by 
macrophages as compared to platelets with high expression of the same HLA-antigens[90]. In 
theory, with such platelets, only HLA-A would have to be considered in the matching 
process.  
No matter which of the methods we use, we need to gain knowledge on which HLA antigens 
that are important in matching. Are all antibodies a barrier to a successful transfusion or are 
some more relevant in vivo? Are there certain HLA alleles that are more immunogenic and 
more easily leads to alloimmunization? One possible study design for increasing the 
understanding could be to purify antibodies to different HLA alleles and study them in an 
animal transfusion model.  
Some recently published studies have started to gain knowledge on the variability in response 
to platelet transfusions in patients with anti-HLA antibodies. It has been shown that a subset 
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of anti-HLA IgG-antibodies induces FcγRIIa-dependent platelet activation and enhanced 
phagocytosis[81]. The authors discuss that affinity of the antibodies are partly responsible for 
the different abilities to activate platelets. They also hypothesize that the specific binding site 
is of importance for whether the Fc tail of an anti-HLA antibody can bind and crosslink with 
FcγRIIa. The same group showed in later publication that a subset of anti-HLA IgG induced 
complement activation via the classical pathway, resulting in permeabilization of platelet 
membranes and increased calcium influx[83]. Interestingly, a very recent publication tried 
eculizumab, a complement C5 inhibitor, in 10 refractory hematology patients to overcome 
platelet refractoriness. They found that treatment with Eculizumab resulted in successful 
transfusions in 40% of the patients, and the effect seemed to last for the two-week study 
period[143]. Eculizumab is presently not usable in routine care due to the high cost of the 
drug. It could however be a possibility in the bleeding refractory patient not responding to 
platelet transfusions or other hemostatic treatment. Linking the research mentioned above 
together, it could be possible that only some subsets of anti-HLA IgG induce complement 
activation and patients with these antibodies would then have a benefit of Eculizumab. This 
would have to be clarified before recommending this treatment in clinical practice.  
Further clarification of the characteristics of anti-HLA antibodies and their receptors on 
platelets would surely bring valuable understanding on which HLA antigens are important in 
matching. As an example, antibodies causing fetal neonatal alloimmune thrombocytopenia 
(FNAIT) have been found to have a decreased Fc fucosylation. The low levels of Fc 
fucosylation led to higher affinity to the receptor FcgRIIIa/b and enhanced phagocytosis. No 
such decrease was found in patients with refractory thrombocytopenia due to anti-HLA 
antibodies[144], but continued investigation would be of interest.  
5.3 HLA DEFICIENT PLATELETS (PAPERS III AND IV) 
In Paper III we evaluated the function of HLA deficient platelets after acid treatment. In 
summary we found that acid-treated platelets were viable and that they upregulated activation 
markers normally. The HLA deficient platelets also aggregated to a similar extent as 
untreated platelets in response to stimulation with three natural agonists. Acid treatment 
removed 70 to 90% of HLA Class I complexes from the platelet surface, which led to 
complete protection from HLA antibody-mediated complement lysis and reduced monocyte-
mediated phagocytosis in the presence of anti-HLA in vitro. 
In Paper IV we further evaluated the function of HLA deficient platelets by extending the 
acid treatment protocol to whole transfusion units (platelet concentrates) and investigating the 
survival of transfused platelets in a mouse model. We found that recovery, HLA reduction, 
and viability in the acid-treated platelet bags were comparable to the small-scale treatment 
protocol. The acid-treated platelets contributed normally to clot formation as assessed by 
Rotem. The HLA deficient platelets also contributed to endothelial integrity. There were no 
signs of HLA re-association during storage of acid-treated platelets. Acid-treated platelets 
showed a lower in vivo recovery than untreated platelets in the mouse model. They were 
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protected from rejection by single HLA allele-specific antibodies, but still cleared by the 
clone W6/32.  
The current approach in platelet refractory patients is HLA matching. As discussed in Paper 
II this is an effective approach only in a certain percentage of cases. Alternatives to HLA 
matching would be welcome both regarding patient safety, quality of life and healthcare 
costs. The production of HLA deficient platelets is an attractive approach as it can be readily 
available within 2-3 hours, using platelets that are already in store at the blood bank, however 
the evidence of its efficiency is lacking. The previous few transfusions reported showed 
mixed results, as discussed in the introduction of this thesis. The study presented in paper III 
was purely pre-clinical and did not test the effect of HLA deficient platelet transfusions in 
patients, however it was the first study to test whether acid treatment protects platelets from 
complement activation and phagocytosis. This approach was of importance to evaluate the 
chance of clinical success in a larger patient population with such a product.  
A drawback of our study is that the HLA genotype of platelet donors was not known. On the 
other hand, the transfusion products were all buffy coat platelets from 6-8 donors and a 
variety of HLA alleles were undoubtedly present. As discussed in the previous part on paper 
II, platelets are known to have a variant expression of HLA and platelets with a low 
expression would likely not induce strong binding of anti-HLA antibodies and subsequent 
phagocytosis.  
Using an animal model has clear limitations, and the use of human platelets in a genetically 
modified mouse calls for cautious conclusions. In our mouse model, the acid-treated platelets 
were cleared faster from the circulation in the mouse model than untreated or control-treated 
platelets. The reason for this is so far unknown but it is reasonable to assume that platelet 
changes due to the acid treatment makes them more prone to clearing. This would need to be 
further investigated, both as an attempt to improve acid treatment before a clinical trial but 
also to gain increased knowledge of platelet biology. Interestingly, in paper III the acid 
treatment per se did not make the platelets prone to phagocytosis by monocytes, neither did 
they activate the complement cascade in the presence of anti-HLA antibodies in contrast to 
both untreated and control-treated platelets, however this was only tested in vitro. Cold 
storage of platelets results in complex storage lesions[145]. Chilled platelets are also cleared 
faster from the circulation but it was recently published that they provided adequate 
hemostasis when given to bleeding patients[62]. It has been shown that such platelets cluster 
their VWF receptors, leading to the recognition of these platelets by hepatic macrophage 
complement type 3 (CR3) receptors[67]. We cannot exclude that the short part of the acid 
treatment that is performed on ice would induce cold-related damage, but there are no 
publications supporting that this would be the case. The control-treated platelets also did not 
clear faster, further supporting that other factors are responsible for activation and clearance. 
It has been shown that loss of HLA might make cells more susceptible to NK cell killing. 
However, in an ongoing study by our group (not published) HLA deficient platelets were not 
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killed by NK cells. We believe this is due to platelets not having activating receptors for NK 
cells.  
Proteomic studies could be one way to further dissect the effect of cold- and acid-treatment. 
For example, as mentioned in the introduction, platelets loose sialic acid in the aging process 
and this leads to phagocytosis. This is something that we have not studied in the acid treated 
platelets so far. Modifications could likely be done to improve our acid treatment protocol, 
and better understanding om the molecular changes induced by the acid treatment would be 




In paper I we studied platelet function in patients with severe thrombocytopenia and 
examined the effect of a platelet transfusion. We found that platelet function and clot 
formation improved after transfusion, and that this is likely due to the better function of the 
transfused platelets compared to the patients’ own platelets. The patients’ platelets were 
impaired in function compared to healthy controls. This is, to my knowledge, one of the few 
studies linking flow cytometry and Rotem assays in thrombocytopenic patients. We found 
that poor platelet function measured by flow cytometry was correlated to impaired clot 
formation, and our study could be a part of continuous work towards new standards for 
assessing platelet function and the need for platelet transfusions.  
In paper II we evaluated different strategies for HLA-matching of platelet transfusions to 
platelet refractory patients. We found that matching by DSA was strongly correlated to 
transfusion outcome, and that transfusions with no DSAs or a complete HLA-A and -B match 
were highly successful. Matching by DSA is recommended, but the risk of further 
alloimmunisation should be considered.  
In paper III and IV we evaluated the effect of acid treatment on platelets. Our results take 
acid-treated platelets closer to being tested in patients. However, possible solutions for the 
reduced in vivo recovery and the remaining susceptibility to clearance by broadly specific 




7 FUTURE PROSPECTS 
Platelet transfusions represent an important part of supportive care for patients with 
hematologic diagnoses and severe thrombocytopenia. Platelet transfusions come with risks 
and it is a clinical challenge to transfuse the right patient at the right time. Continuous 
research is necessary to optimize transfusion strategies further. At present it is understood that 
many of the prophylactically transfused patients would never have had a serious bleeding. 
More precise methods to assess whether a patient suffers from a severe coagulopathy or not 
could contribute to reduce the transfusion frequency. This would be beneficial for the 
individual patient as well as lowering healthcare costs. Development of a clinical scoring 
system including for example platelet count, flow cytometry and a platelet aggregometry test 
such as ROTEM could be one possibility. The great challenge is to find the clinically most 
valid measurements, and a large multicenter study would probably be of immense value. In 
the future we will certainly be able to better predict both bleeding risk and transfusion 
outcome in hematological patients.   
Paper I was very much a hypothesis generating study and left us with more questions than we 
began with. Our results imply that functional recovery of transfused platelets is of importance 
for overall hemostasis, but we could not with certainty differ between autologous and 
allogeneic platelets in our study. In future studies we plan to adopt the technique of 
transfusing platelets mismatched for HLA or HPA, allowing for discrimination between 
patient platelets and transfused platelets. 
Our studies on constructed thrombocytopenic blood could also be further developed with 
almost endless possibilities. This in vitro assay could be used to assess the effect of anemia 
and leukopenia on clot formation and platelet function. Several different platelet agonists can 
be tested, one by one or in combination. The latter approach is attractive, considering that 
agonists rarely exist alone in vivo but rather simultaneously at different concentrations. 
Platelet activation in vitro by co-stimulation of two or more agonists has not been extensively 
investigated so far. In further experiments blocking antibodies could also be used, to dissect 
the role of each of the agonists and to simulate poor granule release function for example.   
Further, including other hematological diagnoses such as lymphoma would likely shed more 
light on the question and could be performed based on the results from our and other studies. 
Considering that there seem to be no significant difference between prophylactic transfusions 
or no-prophylaxis in grade 3 and 4 bleedings in patients with lymphoma undergoing 
autologous stem cell transplantation, it would be very interesting to see if this could partly be 
explained by a better platelet function.  
Besides the above-mentioned aspects, it would be of interest to further investigate the reason 
for platelet function impairment in AML patients and how this impairment resolves during 
the treatment course. Both bone marrow environment, effect of cytostatic drugs and the effect 
of thrombocytopenia could possibly contribute. Platelet function should be studied during the 
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disease course as well as after full remission. In such a study it would be of great interest to 
include IPF and size (mean platelet volume) in relation to platelet activity and hemostasis. 
In a perfect world there would be a registry with a donor for each platelet refractory patient, 
no matter how rare or complex their HLA type is. However, even in that perfect world there 
would still be acute situations where transfusions need to be given as soon as possible. 
Therefore, continued work on improving the protocol for acid treatment of platelets should be 
pursued before continuing with a controlled clinical study in humans. Increased knowledge of 
the effect of acid treatment could also lead to greater understanding of platelet biology and 
the mechanism behind refractoriness. Clearance mechanisms for the acid treated platelets 
need to be further addressed in new animal studies using the mouse model constructed for 
paper IV. For example, it would be of interest to study where the platelets end up 
immediately after transfusion and where they can be found a few hours later.  
In giving the right patient a platelet transfusion at the right time, the next challenge is 
predicting the response or choosing the right platelet product. Much greater knowledge is 
needed of the immunological mechanisms behind platelet clearance and function of the 
allogeneic platelets after transfusion. We could show that the ability of the platelets in the 
concentrate to respond to stimulation with TRAP correlated to the activation of the platelets 
in the patient one hour after transfusion. Further knowledge of different characteristics in the 
platelet concentrate and the in vivo effect will certainly be beneficial for the patients.  
Finally, attempts have been made to make platelets from different kind of progenitor cells. So 
far this has not been successful to the extent that it could replace platelets from blood donors. 
If one gets to speculate about the future this would perhaps be the most exciting breakthrough 













8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
I människan är benmärgen kroppens blodbildande organ d.v.s. kroppens blodfabrik som 
tillverkar bland annat de röda och vita blodkropparna samt blodplättarna. Blodplättar 
(trombocyter) har som funktion att levra blodet och på så vis stoppa upp blödningar. 
Hematologi betyder läran om blodet och inom den medicinska specialiteten hematologi 
arbetar man med att utreda och behandla blodsjukdomar. Exempel på allvarliga 
blodsjukdomar är akuta former av blodcancer (leukemi) samt Myelodysplastiskt syndrom 
(MDS). Patienter med dessa sjukdomar kan ha för lågt antal blodplättar i blodet såväl av 
sjukdomen i sig som ger dålig benmärgsfunktion men också av den kraftfulla 
cytostatikabehandlingen som ges för att behandla sjukdomen. Att ha för låga nivåer av 
blodplättar innebär en ökad risk för blödningar, ibland livshotande, och blodtransfusioner 
med blodplättar kan vara livsavgörande för dessa patienter. Blodtransfusioner med blodplättar 
är dock inte helt utan risk då allergiska transfusionsreaktioner förekommer. Tidigare var 
förorening med bakterier i blodplättspåsen under lagringstiden från blodgivning till 
blodtransfusion ett återkommande problem, men med nya metoder för bakterieavdödning har 
denna risk minskat.   
Effekten av en transfusion med blodplättar mäts ofta utifrån om antalet blodplättar i blodet 
har ökat efter transfusionen. Denna ökning tolkas som ett mått på hur många av de 
transfunderade blodplättarna som har överlevt och återfinns i blodbanan vid tidpunkten för 
blodprovstagningen. När transfusioner med blodplättar ges till patienter med blodsjukdomar 
är det svårt att förutsäga om transfusionen kommer att ha en bra effekt. Ordet refraktär 
betyder oemottaglig eller okänslig. Refraktäritet kallas tillstånd där en patient vid upprepade 
tillfällen får en väldigt liten eller ingen ökning av antalet blodplättar efter en transfusion. 
Tillstånd som blödning, feber och infektion bidrar till en sämre överlevnad av de 
transfunderade blodplättarna och kan bidra till refraktäritet.  
Ett annat tillstånd som kan orsaka refraktäritet är om patienten har bildat antikroppar mot 
HLA klass I (human leukocyte antigen). HLA är strukturer (molekyler) som finns på ytan på 
olika celler, inklusive blodplättar, och som är viktiga för immunförsvaret. Vi har alla vår egen 
individuella uppsättning av HLA, där man ärver hälften från sin mamma och den andra 
hälften från sin pappa, och det finns mer än 9000 olika varianter. Vid graviditet, 
blodtransfusioner och benmärgs- och organtransplantationer kommer vårt immunförsvar i 
kontakt med främmande celler med främmande HLA-molekyler på ytan och då bildas ibland 
antikroppar mot dessa främmande HLA. Om en patient som har antikroppar mot en viss 
HLA-typ får en transfusion med blodplättar från en givare med just den HLA-typ som 
patienten har antikroppar mot finns en risk att de transfunderade blodplättarna attackeras av 
patientens immunförsvar och förstörs. I dessa fall får patienten en dålig effekt av sin 
transfusion och i vissa fall även en transfusionsreaktion, som kan yttra sig som feber och 
frossa eller i allvarliga fall blodtrycksfall och allergisk chock. Patienter med refraktäritet och 
antikroppar mot HLA kan få transfusioner med blodplättar som är matchade för att passa med 
patientens HLA-typ. Ett annat alternativ är att avlägsna HLA-molekyler från ytan på de 
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blodplättar som skall transfunderas genom att pH-värdet runt blodplättarna sänks under kort 
tid med en så kallad syrabehandling. HLA-molekylerna förlorar då sin struktur och vår 
hypotes är att detta leder till att blodplättarna undkommer HLA-antikropparna och överlever 
bättre efter transfusion. Syrabehandlade blodplättar användes till transfusioner till enstaka 
patienter på 90-talet men därefter infördes filtrering av blodprodukter vilket minskade antalet 
patienter som utvecklade antikroppar mot HLA.  
Vid benmärgssjukdom är det ej helt känt hur patienternas egna trombocyter eller hur 
transfunderade blodplättar fungerar i patienten efter en transfusion. För att mäta 
blodplättarnas funktion (trombocytfunktionen) mäter man deras förmåga att svara på olika 
signaler i kroppen och bidra till koagelbildning för att stoppa blödning. Trombocytfunktionen 
kan undersökas med olika metoder. Med flödescytometri kan man undersöka celler i en 
vätska med hjälp av laserljus, man kan då bland annat analysera hur blodplättarna ser ut på 
ytan med och utan olika stimulerande ämnen. ROTEM (rotational thromboelastometry) är ett 
instrument som ger en övergripande bild av hur blodet koagulerar i ett blodprov. 
I denna avhandling studeras trombocytfunktion i patienter före och efter transfusion med 
blodplättar samt hur väl refraktära patienter svarar på HLA-matchade transfusioner. Vidare 
undersöktes funktionen av syrabehandlade blodplättar med olika laboratoriemetoder och i en 
musmodell. I det första delarbetet undersöktes blodplättar i blodprov från 40 hematologiska 
patienter före transfusion, en timme efter transfusion och 18 till 24 timmar efter transfusion. 
Vi undersökte antalet blodplättar, koagelbildning och hur blodplättarna svarade på 
stimulerande ämnen. Ökningen av antalet blodplättar var kopplad till förbättrad 
koagelbildning, men hur patienter svarade på transfusionen varierade avsevärt och 34% fick 
ett dåligt svar på transfusionen. I patienter som svarade bra på transfusionen var en effektiv 
koagelbildning korrelerad till bra svar på stimulerande ämnen men transfusionen förbättrade 
inte trombocytfunktionen till samma nivå som hos friska blodgivare.  
I det andra delarbetet undersöktes hur väl refraktära patienter svarade på HLA-matchade 
transfusioner med blodplättar. Vi fann att blodplättar som var helt matchade, där givare och 
patient har exakt samma HLA klass I typ, i stor utsträckning förutspådde ett bra 
transfusionssvar. En acceptabel ofullständig matchning, där patienten ej hade antikroppar mot 
det eller de HLA-molekyler som skiljde mellan givare och patient, kunde i ungefär samma 
utsträckning förutsäga ett bra transfusionssvar. Många transfusioner var också lyckade trots 
att patienten hade antikroppar mot givarens HLA.  
I det tredje delarbetet undersöktes funktionen av syrabehandlade blodplättar. Vi fann att 
syrabehandlingen inte påtagligt försämrar trombocyternas funktion och att syrabehandlade 
blodplättar kan undkomma immunförsvarets attack och därmed undgår förstörelse. 
Syrabehandling tog bort 70 till 90% av HLA klass I molekyler på blodplättarnas yta.  
I det fjärde delarbetet undersöktes funktionen av syrabehandlade blodplättar ytterligare och 
ett protokoll utvecklades för att syrabehandla blodplättar i en hel transfusionspåse för att 
möjliggöra en senare studie i refraktära patienter. Vi undersökte också hur de syrabehandlade 
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blodplättarna överlevde i möss. Vi fann att blodplättarnas återhämtning, minskning av HLA-
molekyler och viabilitet (livskraftighet) var jämförbart i de syrabehandlade 
transfusionspåsarna och i mindre skala med en liten mängd syrabehandlade blodplättar. De 
syrabehandlade blodplättarna bidrog på ett normalt sätt till koagelbildning i ROTEM 
instrumentet. I musmodellen visade de syrabehandlade blodplättarna en kortare överlevnad 
jämfört med obehandlade blodplättar. De var skyddade från att förstöras i närvaro av 
antikroppar som bara binder till specifika undergrupper av HLA men inte vid närvaro av 
HLA-antikroppar som binder till de flesta HLA-molekyler.  
Sammanfattningsvis presenterar avhandlingen resultat och slutsatser som har lett till ändrade 
rutiner på Blodcentralen på Karolinska Universitetssjukhuset avseende hur blodplättar väljs 
ut för transfusion till refraktära patienter. Resultatet i det första delarbetet kommer att 
användas för fördjupade analyser av blodplättars funktion i relation till transfusion och även i 
relation till olika hematologiska diagnoser, behandlingar och sjukdomsförlopp. Resultaten i 
delarbete tre och fyra har tagit syrabehandlade blodplättar några steg närmare en framtida 
forskningsstudie på människor med transfusion av syrabehandlade blodplättar till refraktära 
patienter.  
Strävan efter att förbättra transfusionsrutiner bör fortsätta med det bästa för såväl patienter 









I would like to acknowledge Region Stockholm who supported these studies by providing me 
with a research residency position. The time and financial support have facilitated this thesis.  
The PhD journey can be described in many ways. My favorite illustration on the subject, not 
shared here due to copyright reasons, is that of the thought journey as a straight road, while 
the true journey provides obstacles in form of deep rivers and high mountains. It turned out to 
be truer than I could have ever imagined, but thanks to the enormous help of so many people 
I managed to swim across the deepest rivers and climb to the top of the highest mountains. I 
would like to specifically acknowledge:  
The patients and blood donors for participating in the prospective study.  
My main supervisor Petter Höglund for the endless positive attitude, for always seeing life 
and research from the bright side, for support during the hard times and pure happiness 
during the rest! And of course, for believing in me and giving me the opportunity to pursue 
my PhD.  
My co-supervisor Agneta Wikman for all the support and encouragement, for sharing your 
knowledge and ideas and for reviewing my paper with valuable comments.  
My co-supervisor Per Sandgren for providing the platelets for study III and IV and sharing 
my fascination for them. For always answering every question with a smile.  
My co-supervisor and friend Stephan Meinke for baring with me during the early years, for 
having by back at the flow cytometer, for listening to my ideas and enthusiastically 
discussing them.  
Eva Hellström Lindberg, for creating the amazing place that HERM is, for agreeing to be 
the chairperson for my defense and for being an outstanding and highly valuable colleague in 
the clinic.  
A very warm thank you to Gunilla Gryfelt who came into my research journey at a time 
when I really needed someone to help me with the patient sample analyses. Without you, 
study I would still not have been completed and I would probably not have been defending 
this thesis any time soon… Further, you have been a good friend and I appreciate our 
conversations immensely.  
Jacob Odeberg, my mentor. Time and distance did not really allow us to meet as often as I 
would have liked, but I have kept your valuable words with me during these years of my 
thesis work. You are truly an inspiration.  
My friend and research colleague Thuy, you have been such an inspiration during these 
years. I have enjoyed our biking excursions and ski trips immensely and look forward to 
continuing this tradition.  
 
46 
My friend, colleague, and research partner Jenny. For sharing work- and research life the 
past seven years. I look forward to us continuing working together.  
Nadir. You are one of the warmest and most including people I know. I wish we get to 
continue to share laughs and happy times in the future, whatever it may hold for us.  
All the Höglund research group and associate members. Stephan, Thuy, Nadir, Sridharan, 
Laurent, Javad, Suria, Corinna, Paul, Axel, Arnika and Sophia. Some already mentioned, 
but worth mentioning again. For great scientific discussions and friendships alike.  
All former and current colleagues at HERM, I will not mention you all by name out of fear 
of forgetting someone. You have all contributed to the fantastic research environment that has 
kept me going all these years.  
All co-authors of the research papers, for the great collaboration and invaluable contribution 
from each and every one of you.  
All outstanding colleagues at the Medical Unit Hematology at Karolinska University 
Hospital, you are the reason I arrive at work with a smile every day.  
Daniel, my partner in crime and life, and my greatest support. Your bizarre but impeccable 
sense of humor keeps me going!  
Dexter and Lexie, my beautiful children. For giving me grey hair but making me want to be 
a better person every single day.  
My parents, Ingrid and Ola, for unconditional love and support throughout the years, and for 
believing in me no matter what.  
My in-laws, Ing-Mari and Dan, for accepting me into the family and always welcoming us 
to your home. I am so sad that we missed Easter, Midsummers and Christmas together this 
strange Corona-year, but I look forward to many many celebrations in the future.  
My brother in-law, Tim, for all the interesting discussions we have had and remembering my 
birthday every single year since we first got to know each other.  
My aunt Kerstin and my cousin David, for all the happy times we have had and will have, 
celebrating birthdays and holidays together.  
My dear friend Emelie, for travelling with me and the kids, for always being there and never 
letting me feel alone.  
My dear friend Sophia, for being my unbiological sister and private (however, unpaid) 
psychologist. For sharing happy and hard times likewise.  
The rest of “the Supernovas”, for a fantastic friendship that has lasted 23 years and will last 
many, many more.  
 
 47 
My friend Linda, for always making me laugh when I need it the most. For reading this 
thesis and giving great feedback.  
Monika, our mountainbike trips have been therapeutic and a very welcome break from work 
and research, a time to refill energy.   
The rest of the “thirtysomething-women”. We have shared both happiness and grief during 
the ten years we have known each other. You have been an invaluable support in small things 
as well as life-changing experiences. Let us continue to be the amazing group of amazing 










1. Michelson AD. Platelets. 3 ed: Academic Press; 2013 10th December 2012. 
1398 p. 
2. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of 
thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion. 
1974;14(5):440-6. 
3. Woolthuis CM, Park CY. Hematopoietic stem/progenitor cell commitment to 
the megakaryocyte lineage. Blood. 2016;127(10):1242-8. 
4. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. 
Cell Stem Cell. 2012;10(2):120-36. 
5. VI. An account of certain organisms occurring in the liquor sanguinis. 
Proceedings of the Royal Society of London. 1997;22(148-155):391-8. 
6. Coller BS. Historical perspective and future directions in platelet research. 
Journal of Thrombosis and Haemostasis. 2011;9:374-95. 
7. Kaushansky K. Thrombopoiesis. Semin Hematol. 2015;52(1):4-11. 
8. Ebaugh FG, Bird RM. The Normal Megakaryocyte Concentration in Aspirated 
Human Bone Marrow. Blood. 1951;6(1):75-80. 
9. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human 
thrombopoietin in thrombocythaemic sera. Acta Haematol. 1958;20(6):350-5. 
10. George JN. Platelets. The Lancet. 2000;355(9214):1531-9. 
11. Behnke O, Forer A. From megakaryocytes to platelets: platelet morphogenesis 
takes place in the bloodstream. Eur J Haematol Suppl. 1998;61:3-23. 
12. Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Regulating billions of 
blood platelets: glycans and beyond. Blood. 2015;126(16):1877-84. 
13. Scharf RE. Platelet Signaling in Primary Haemostasis and Arterial Thrombus 
Formation: Part 1. Hamostaseologie. 2018;38(4):203-10. 
14. Saboor M, Ayub Q, Ilyas S, Moinuddin. Platelet receptors; an instrumental of 
platelet physiology. Pak J Med Sci. 2013;29(3):891-6. 
15. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and 
signaling in the dynamics of thrombus formation. Haematologica. 2009;94(5):700-11. 
16. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound 
healing and beyond. Blood Rev. 2015;29(3):153-62. 
17. Stalker TJ, Traxler EA, Wu J, Wannemacher KM, Cermignano SL, Voronov R, 
et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-
signaling network. Blood. 2013;121(10):1875-85. 
18. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for 
platelets as immune and inflammatory cells. Blood. 2014;123(18):2759-67. 
 
50 
19. Maouia A, Rebetz J, Kapur R, Semple JW. The Immune Nature of Platelets 
Revisited. Transfus Med Rev. 2020. 
20. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, et al. Platelet 
Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and 
tumor necrosis factor-alpha production in vivo. Blood. 2006;107(2):637-41. 
21. Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A 
novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. 
Blood. 2006;107(2):542-9. 
22. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. 
Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat 
Med. 2007;13(4):463-9. 
23. Kim SJ, Jenne CN. Role of platelets in neutrophil extracellular trap (NET) 
production and tissue injury. Semin Immunol. 2016;28(6):546-54. 
24. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. 
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J 
Virol. 2006;80(18):8951-60. 
25. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role 
of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular 
compartment and is enhanced by platelet activation. Blood. 2002;99(11):4021-9. 
26. Banerjee M, Huang Y, Joshi S, Popa GJ, Mendenhall MD, Wang QJ, et al. 
Platelets Endocytose Viral Particles and Are Activated via TLR (Toll-Like Receptor) 
Signaling. Arterioscler Thromb Vasc Biol. 2020;40(7):1635-50. 
27. Zhou M, Qi J, Li X, Zhang Z, Yao Y, Wu D, et al. The proportion of patients 
with thrombocytopenia in three human-susceptible coronavirus infections: a systematic 
review and meta-analysis. Br J Haematol. 2020;189(3):438-41. 
28. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. 
Ann Hematol. 2020;99(6):1205-8. 
29. Boilard E, Pare G, Rousseau M, Cloutier N, Dubuc I, Levesque T, et al. 
Influenza virus H1N1 activates platelets through FcgammaRIIA signaling and thrombin 
generation. Blood. 2014;123(18):2854-63. 
30. Li R, Hoffmeister KM, Falet H. Glycans and the platelet life cycle. Platelets. 
2016;27(6):505-11. 
31. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, 
Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer. 
2012;12:304. 
32. Dombret H, Gardin C. An update of current treatments for adult acute myeloid 
leukemia. Blood. 2016;127(1):53-61. 
33. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson 
TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life 
Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-7. 
34. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. 
Proposed classification of lymphoid neoplasms for epidemiologic research from the 
Pathology Working Group of the International Lymphoma Epidemiology Consortium 
(InterLymph). Blood. 2007;110(2):695-708. 
 
 51 
35. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. 
Harrison's principles of internal medicine. 19 ed: New York: McGraw Hill Education.; 2015. 
36. Duke WW. The Relation of Blood Platelets to Hemorrhagic Disease. Journal of 
the American Medical Association. 1910;55(14). 
37. Gardner FH, Phin C. The Value of Platelet Transfusions. Medical Clinics of 
North America. 1960;44(5):1425-39. 
38. Freireich EJ. Supportive care for patients with blood disorders. Br J Haematol. 
2000;111(1):68-77. 
39. Solves Alcaina P. Platelet Transfusion: And Update on Challenges and 
Outcomes. J Blood Med. 2020;11:19-26. 
40. Blodverksamheten i Sverige 2019. Available from: 
http://sweba.se/filedepot?fid=1200. 
41. Williamson LM, Devine DV. Challenges in the management of the blood 
supply. The Lancet. 2013;381(9880):1866-75. 
42. WHO Fact Sheet on Ageing and health  [2020/12/13]. Available from: 
https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. 
43. Pendry KD, T. . An audit of the use and wastage in the North West of England 
and North Wales - where have all the platelets gone? . 2011. 
44. Estcourt LJ, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy MF. 
Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 
2012;103(4):284-93. 
45. Blajchman MA. Platelet transfusions: an historical perspective. Hematology 
Am Soc Hematol Educ Program. 2008:197. 
46. Murphy S, Gardner FH. Effect of storage temperature on maintenance of 
platelet viability--deleterious effect of refrigerated storage. N Engl J Med. 
1969;280(20):1094-8. 
47. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM. Safety of platelet 
transfusion: past, present and future. Vox Sang. 2014;107(2):103-13. 
48. Logistics of platelet concentrates. Vox Sang. 2007;92(2):160-81. 
49. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, et al. 
The impact of platelet transfusion characteristics on posttransfusion platelet increments and 
clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. 
2012;119(23):5553-62. 
50. Shrivastava M. The platelet storage lesion. Transfus Apher Sci. 
2009;41(2):105-13. 
51. Singh S, Shams Hakimi C, Jeppsson A, Hesse C. Platelet storage lesion in 
interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates. 
Transfusion and Apheresis Science. 2017;56(6):870-4. 
52. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al. 
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of 
platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113(7):1564-73. 
 
52 
53. Beuerlein I, Mariss P, Stangel W. [Studies with radiolabeled autologous and 
heterologous thrombocytes to determine life-span and destruction sites]. Nuclear-Medizin. 
1975;14(3):240-7. 
54. Vetlesen A, Holme PA, Lyberg T, Kjeldsen-Kragh J. Recovery, survival, and 
function of transfused platelets and detection of platelet engraftment after allogeneic stem cell 
transplantation. Transfusion. 2012;52(6):1321-32. 
55. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent 
platelet recovery as measures of posttransfusion platelet response: problems and a solution. 
Transfusion. 1999;39(6):586-92. 
56. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. 
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet 
transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-14. 
57. Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, et al. 
Functional recovery of stored platelets after transfusion. Transfusion. 2016;56(5):1030-7. 
58. Batman B, van Bladel ER, van Hamersveld M, Pasker-de Jong PCM, 
Korporaal SJA, Urbanus RT, et al. Agonist-induced platelet reactivity correlates with 
bleeding in haemato-oncological patients. Vox Sang. 2017;112(8):773-9. 
59. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-
prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 
2013;368(19):1771-80. 
60. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, 
et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with 
haematological malignancies: an open-label, multicentre, randomised study. The Lancet. 
2012;380(9850):1309-16. 
61. Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, et 
al. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex 
Cardiothoracic Surgery. Anesthesiology. 2020;133(6):1173-83. 
62. Warner MA, Kurian EB, Hammel SA, van Buskirk CM, Kor DJ, Stubbs JR. 
Transition from room temperature to cold-stored platelets for the preservation of blood 
inventories during the COVID-19 pandemic. Transfusion. 2020. 
63. Mack JP, Miles J, Stolla M. Cold-Stored Platelets: Review of Studies in 
Humans. Transfus Med Rev. 2020;34(4):221-6. 
64. Kiefel V. Reactions Induced by Platelet Transfusions. Transfus Med Hemother. 
2008;35(5):354-8. 
65. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage 
WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet 
concentrates and RBC. Transfusion. 2004;44(1):10-5. 
66. Jenkins C, Ramirez-Arcos S, Goldman M, Devine DV. Bacterial contamination 
in platelets: incremental improvements drive down but do not eliminate risk. Transfusion. 
2011;51(12):2555-65. 
67. Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas 
TN, et al. The Clearance Mechanism of Chilled Blood Platelets. Cell. 2003;112(1):87-97. 
68. Magron A, Laugier J, Provost P, Boilard E. Pathogen reduction technologies: 
The pros and cons for platelet transfusion. Platelets. 2018;29(1):2-8. 
 
 53 
69. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am 
Soc Hematol Educ Program. 2007:172-8. 
70. Otrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk 
mitigation: an update. Vox Sang. 2017;112(8):694-703. 
71. Sachs UJ. Pathophysiology of TRALI: current concepts. Intensive Care Med. 
2007;33 Suppl 1:S3-S11. 
72. Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. 
Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-
67. 
73. Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? 
Hematology Am Soc Hematol Educ Program. 2020;2020(1):527-32. 
74. Friedberg R, Donnelly S, Boyd J, Gray L, Mintz P. Clinical and blood bank 
factors in the management of platelet refractoriness and alloimmunization. Blood. 
1993;81(12):3428-34. 
75. Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS, et al. Epitope-based 
matching for HLA-alloimmunized platelet refractoriness in patients with hematologic 
diseases. Transfusion. 2010;50(11):2318-27. 
76. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness--
practical approaches and ongoing dilemmas in patient management. Br J Haematol. 
2015;171(3):297-305. 
77. Anaya J-M, Shoenfeld Y, Rojas-Villarraga A, Levy R, Cervera R. 
Autoimmunity. From Bench to Bedside2013. 
78. Swain SL. T cell subsets and the recognition of MHC class. Immunol Rev. 
1983;74:129-42. 
79. Nomenclature for Factors of the HLA System  [2020/12/23]. Available from: 
http://hla.alleles.org. 
80. Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morere D, et al. Platelet 
transfusion refractoriness in patients with acute myeloid leukemia treated by intensive 
chemotherapy. Leuk Res. 2017;61:62-7. 
81. Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FHJ, et al. A subset 
of anti-HLA antibodies induces FcgammaRIIa-dependent platelet activation. Haematologica. 
2018;103(10):1741-52. 
82. Enos AI, Hair PS, Krishna NK, Cunnion KM. A complement-mediated rat 
xenotransfusion model of platelet refractoriness. Mol Immunol. 2020;124:9-17. 
83. Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, et al. Anti-
HLA antibodies with complementary and synergistic interaction geometries promote classical 
complement activation on platelets. Haematologica. 2019;104(2):403-16. 
84. Meinke S, Sandgren P, Mortberg A, Karlstrom C, Kadri N, Wikman A, et al. 
Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by 
complement and phagocytes in the presence of HLA antibodies. Transfusion. 
2016;56(2):370-82. 
85. Meinke S, Karlstrom C, Hoglund P. Complement as an Immune Barrier in 
Platelet Transfusion Refractoriness. Transfus Med Rev. 2019;33(4):231-5. 
 
54 
86. Hess JR, Trachtenberg FL, Assmann SF, Triulzi DJ, Kaufman RM, Strauss RG, 
et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the 
PLADO trial. Vox Sang. 2016;111(3):281-91. 
87. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. 
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: 
implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 
2009;49(9):1825-35. 
88. Novotny VM. Prevention and management of platelet transfusion 
refractoriness. Vox Sang. 1999;76(1):1-13. 
89. Trial to Reduce Alloimmunization to Platelets Study G. Leukocyte reduction 
and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to 
platelet transfusions. N Engl J Med. 1997;337(26):1861-9. 
90. Saris A, Tomson B, Brand A, Mulder A, Claas FH, Lorinser J, et al. Platelets 
from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo 
antibody-mediated internalization. Blood. 2018;131(1):144-52. 
91. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, et al. 
Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and 
refractoriness. Blood. 2004;103(1):333-9. 
92. Porrett PM. Biologic mechanisms and clinical consequences of pregnancy 
alloimmunization. Am J Transplant. 2018;18(5):1059-67. 
93. O'Rafferty C, Rooney G, Hagan R, Woolfson M, O'Donghaile D, Fitzgerald J. 
HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised 
thrombocytopaenic patients who are refractory to random donor platelets. Transfus Med. 
2017;27 Suppl 5:369-74. 
94. Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. 
Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative 
thrombocytopenia: a systematic review. Transfusion. 2013;53(10):2230-42. 
95. Schmidt AE, Refaai MA, Coppage M. HLA-Mediated Platelet Refractoriness. 
Am J Clin Pathol. 2019;151(4):353-63. 
96. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity 
of HLA class I alloantibodies I. Frequency analysis of antibodies to private versus public 
specificities in potential transplant recipients. Human Immunology. 1994;39(4):272-80. 
97. Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized 
thrombocytopenic patients: a new strategy to provide more effective platelet transfusion 
support? Transfusion. 2008;48(2):221-7. 
98. Duquesnoy RJ. A structurally based approach to determine HLA compatibility 
at the humoral immune level. Hum Immunol. 2006;67(11):847-62. 
99. Brooks EG, MacPherson BR, Fung MK. Validation of HLAMatchmaker 
algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients 
refractory to platelet transfusions. Transfusion. 2008;48(10):2159-66. 
100. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of 
platelet products for alloimmune-refractory patients. Transfusion. 2015;55(2):235-44. 
 
 55 
101. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, et al. 
Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. 
Transfusion. 2000;40(12):1446-56. 
102. Blumberg N, Masel D, Mayer T, Horan P, Heal J. Removal of HLA-A,B 
antigens from platelets. Blood. 1984;63(2):448-50. 
103. Shunji S, Toru A, Katsuo K. A simple method to eliminate the antigenicity of 
surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. 
Journal of Immunological Methods. 1987;100(1-2):83-90. 
104. Kurata Y, Oshida M, Take H, Furubayashi T, Nakao H, Tomiyama Y, et al. 
New approach to eliminate HLA class I antigens from platelet surface without cell damage: 
acid treatment at pH 3.0. Vox Sang. 1989;57(3):199-204. 
105. Novotny VM, Doxiadis IN, van Doorn R, Brand A. The kinetics of HLA class I 
elution and the relevance for the use of HLA-eluted platelet transfusions. Br J Haematol. 
1996;95(2):416-22. 
106. Polakova K, Karpatova M, Russ G. Dissociation of β2-microglobulin is 
responsible for selective reduction of HLA class I antigenicity following acid treatment of 
cells. Molecular Immunology. 1993;30(14):1223-30. 
107. Shanwell A, Sallander S, Olsson I, Gulliksson H, Pedajas I, Lerner R. An 
alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-
donor platelets. Br J Haematol. 1991;79(3):462-5. 
108. Novotny VM, Huizinga TW, van Doorn R, Briet E, Brand A. HLA class I-
eluted platelets as an alternative to HLA-matched platelets. Transfusion. 1996;36(5):438-44. 
109. Sivakumaran M, Rajapakse R, Pavord S, Revill J, Clarke C. Treatment of 
alloimmunized, thrombocytopenic patient with acid-treated random donor platelets. Br J 
Haematol. 1992;81(1):134-5. 
110. Castro E, Muncunill J, Barea L, Gonzalez R, Fernandez-Villalta MJ. Acid 
elution of platelets HLA-class I antigens in the treatment of a refractory patient. Br J 
Haematol. 1998;100(1):245-6. 
111. Eto K. Platelets using iPS cell technology; large scale manufacturing. Journal of 
Stem Cells and Regenerative Medicine. 2019;15(2). 
112. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, 
et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 
2010;362(7):600-13. 
113. Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ. 
Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding 
outcomes in the PLADO trial. Blood. 2017;130(10):1247-58. 
114. McKinnon KM. Flow Cytometry: An Overview. Curr Protoc Immunol. 
2018;120:5 1 -5 1 11. 
115. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet 
membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 
1985;260(20):11107-14. 
116. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of 
thromboelastography in clinical coagulation management and transfusion practice. Transfus 
Med Rev. 2012;26(1):1-13. 
 
56 
117. Trauma Induced Coagulopathy 2016. Available from: 
https://doi.org/10.1007/978-3-319-28308-1. 
118. Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic 
disease. Curr Pharm Des. 2012;18(33):5379-91. 
119. Hanke AA, Roberg K, Monaca E, Sellmann T, Weber CF, Rahe-Meyer N, et al. 
Impact of platelet count on results obtained from multiple electrode platelet aggregometry 
(Multiplate). Eur J Med Res. 2010;15(5):214-9. 
120. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. 
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice 
constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24(10):1785-8. 
121. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet 
count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905-9. 
122. Estcourt LJ, Stanworth SJ, Harrison P, Powter G, McClure M, Murphy MF, et 
al. Prospective observational cohort study of the association between thromboelastometry, 
coagulation and platelet parameters and bleeding in patients with haematological 
malignancies- the ATHENA study. Br J Haematol. 2014;166(4):581-91. 
123. Just Vinholt P, Højrup Knudsen G, Sperling S, Frederiksen H, Nielsen C. 
Platelet function tests predict bleeding in patients with acute myeloid leukemia and 
thrombocytopenia. American Journal of Hematology. 2019;94(8):891-901. 
124. Gunduz E, Akay OM, Bal C, Gulbas Z. Can thrombelastography be a new tool 
to assess bleeding risk in patients with idiopathic thrombocytopenic purpura? Platelets. 
2011;22(7):516-20. 
125. Savage B, Ruggeri Z. Selective recognition of adhesive sites in surface-bound 
fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. The Journal of biological 
chemistry. 1991;266 17:11227-33. 
126. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab 
Hematol. 2009;31(3):277-97. 
127. McDonnell A, Bride KL, Lim D, Paessler M, Witmer CM, Lambert MP. Utility 
of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from 
bone marrow failure and predicting bleeding risk. Pediatr Blood Cancer. 2018;65(2). 
128. Thompson CB, Monroy RL, Skelly RR, Quinn PG, Jakubowski JA. The 
Biology of Platelet Volume Heterogeneity. In: Martin J, Trowbridge A, editors. Platelet 
Heterogeneity: Biology and Pathology. London: Springer London; 1990. p. 25-37. 
129. Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, 
Anagnostopoulos A, et al. Eltrombopag for advanced myelodysplastic syndromes or acute 
myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-
controlled, phase 2 trial. The Lancet Haematology. 2018;5(1):e34-e43. 
130. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, et al. 
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia 
compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb 
Haemost. 2011;9(11):2302-10. 
131. Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond the platelet 
count: immature platelet fraction and thromboelastometry correlate with bleeding in patients 
with immune thrombocytopenia. Br J Haematol. 2014;166(4):592-600. 
 
 57 
132. van Bladel ER, Laarhoven AG, van der Heijden LB, Heitink-Pollé KM, 
Porcelijn L, van der Schoot CE, et al. Functional platelet defects in children with severe 
chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood. 
2014;123(10):1556-63. 
133. Connor DE, Ma DD, Joseph JE. Flow cytometry demonstrates differences in 
platelet reactivity and microparticle formation in subjects with thrombocytopenia or 
thrombocytosis due to primary haematological disorders. Thromb Res. 2013;132(5):572-7. 
134. Foss B, Bruserud O. Platelet functions and clinical effects in acute 
myelogenous leukemia. Thromb Haemost. 2008;99(1):27-37. 
135. Leinoe EB, Hoffmann MH, Kjaersgaard E, Johnsen HE. Multiple platelet 
defects identified by flow cytometry at diagnosis in acute myeloid leukaemia. Br J Haematol. 
2004;127(1):76-84. 
136. Queisser W, Queisser U, Ansmann M, Brunner G, Hoelzer D, Heimpel H. 
Megakaryocyte polyploidization in acute leukaemia and preleukaemia. Br J Haematol. 
1974;28(2):261-70. 
137. Jinnai I, Tomonaga M, Kuriyama K, Matsuo T, Nonaka H, Amenomori T, et al. 
Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) 
leukaemia and implication for poor response to chemotherapy. Br J Haematol. 
1987;66(4):467-72. 
138. Wong KF, Chan JK. Are 'dysplastic' and hypogranular megakaryocytes specific 
markers for myelodysplastic syndrome? Br J Haematol. 1991;77(4):509-14. 
139. Nouvel C, Caranobe C, Sie P, Capdeville J, Pris J, Boneu B. Platelet volume, 
density and 5 HT organelles (mepacrine test) in acute leukaemia. Scandinavian journal of 
haematology. 1978;21(5):421-6. 
140. Takahashi K, Juji T, Miyazaki H. Determination of an appropriate size of 
unrelated donor pool to be registered for HLA-matched platelet transfusion. Transfusion. 
1987;27(5):394-8. 
141. Marsh JC, Stanworth S, Pankhurst LA, Kallon D, Gilbertson A, Pigden C, et al. 
An epitope-based approach to use of HLA matched platelets for transfusion: a noninferiority, 
cross-over, randomised trial. Blood. 2020. 
142. Schiffer CA, O'Connell B, Lee EJ. Platelet transfusion therapy for 
alloimmunized patients: selective mismatching for HLA B12, an antigen with variable 
expression on platelets. Blood. 1989;74(3):1172-6. 
143. Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, et al. A pilot trial of 
complement inhibition using eculizumab to overcome platelet transfusion refractoriness in 
human leukocyte antigen allo-immunized patients. Br J Haematol. 2020;189(3):551-8. 
144. Kapur R, Kustiawan I, Vestrheim A, Koeleman CA, Visser R, Einarsdottir HK, 
et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. 
Blood. 2014;123(4):471-80. 
145. Hegde S, Wellendorf AM, Zheng Y, Cancelas JA. Antioxidant prevents 
clearance of hemostatically competent platelets after long-term cold storage. Transfusion. 
2020. 
 
